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1.1	Forewords:	powers	of	10
There	are	some	questions	the	seniors	of	us	have	answered	tens	of	times	when	advising	younger	researchers	at	their	first	experiences	with	electrophoresis	and	proteomics.	One	of	them	is	how	to	remove	albumin
from	plasma/serum	and	other	biological	fluids	before	analysis.	We	challenge	that	this	question	is	in	fact	the	most	appropriate.	We	maintain,	first,	that	all	major	proteins	in	those	samples	are	at	issue;	then,	that	a	proper
question	should	be,	instead,	when	to	remove	them	and	when	do	not.	In	the	following,	we	are	going	to	present	our	point	of	view	–	—	which	we	know	is	not	shared	by	the	majority	of	the	scientific	community.	Most	of	the
information	will	focus	on	human	specimens	although	similar	concepts	and	procedures	apply	to	plasma/serum	from	laboratory	and	farm	animals	as	well.
Clinical	biochemistry	has	long	recognized	that	the	concentration	in	blood	of	tissue	components	increases	as	a	result	of	tissue	damage.	The	recognition	of	tissue-specific	isoforms,	either	as	sequence	variants	or
as	 heteromultimeric	 assembly	 variants,	 has	 been	 the	 basis	 for	 discriminating	 tissue	 origin.	 The	 difference	 in	 subcellular	 derivation	 (plasma	 membrane,	 cytoplasm,	 mitochondria)	 has	 been	 associated	 with
nature/severity/duration	of	the	noxa.	The	typical	intracellular	proteins	currently	quantitated	in	blood	by	the	clinical	biochemistry	laboratory	are	medium-abundance	enzymes,	assayed	through	their	catalytic	activity,	and
high-abundance	structural	proteins,	identified	through	their	immunological	reactivity.
Either	innovative	or	more	effective	disease	markers	should	be	as	sharply	as	possible	both	tissue-	and	disease-specific.	Proteomics	studies	have	demonstrated	that	some	major	biological	limitations	exist	in	these
directions.	The	thorough	investigation	about	the	tissue	distribution	of	gene	products	in	different	organs	and	cell	types	carried	out	under	 ‘The	Human	Protein	Atlas’	project	–	—	which	participates	 in	 the	overall	 ‘The
Review	aArticle
With	or	without	you	‐	—	Proteomics	with	or	without	major	plasma/serum	proteins
Elisabetta	Gianazza1a,	⁎
elisabetta.gianazza@unimi.it
Ingrid	Miller2b
Luca	Palazzolo1a
Chiara	Parravicini1a
Ivano	Eberini1a
1aDipartimento	di	Scienze	Farmacologiche	e	Biomolecolari,	Università	degli	Studi	di	Milano,	Via	Balzaretti	9,	I-20133	MilanoMilan,	Italy
2bInstitut	für	Medizinische	Biochemie,	Veterinärmedizinische	Universität	Wien,	Veterinärplatz	1,	A-1210	Wien,	Austria
⁎*Corresponding	author.
Abstract
The	first	sections	of	this	review	compile	and	discuss	strategies	and	protocols	for	managing	plasma/serum	as	a	source	of	biomarkers	relevant	to	human	disease.	In	many	such	cases,	depletion	of	abundant
protein(s)	is	a	crucial	preliminary	step	to	the	procedure;	specific	conceptual	and	technical	approaches,	however,	make	it	possible	to	effectively	use	to	this	purpose	whole	plasma/serum.	The	final	sections
focus	instead	on	the	complexity	associated	with	each	of	the	major	serum/plasma	proteins	in	terms	of	both,	multiple	molecular	structures	(existence	of	a	number	of	protein	species)	and	of	multiple	molecular
functions	(behavior	as	multifunctional/multitasking/moonlighting	proteins).	Reviewing	evidence	in	these	and	some	related	fields	(regulation	of	the	synthetic	pattern	by	proteins	and	non-protein	compounds
and	its	connection	with	health	and	disease)	prompts	the	suggestion/recommendation	that	information	on	the	abundant	components	of	plasma/serum	proteome	is	routinely	obtained	and	processed/mined	as	a
valuable	contribution	to	the	characterization	of	any	non-physiological	condition	and	to	the	understanding	of	its	mechanisms	and	of	its	implications/sequels.
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Human	Proteome’	endeavor	‐	—	has	demonstrated	that	differences	in	proteome	composition	among	cell	types	are	more	of	a	quantitative	than	of	a	qualitative	nature.	Absolute	tissue	specificity	has	been	demonstrated	only	for	a
small	percentage	of	proteins,	the	most	obvious	of	which	had	been	known	for	decades.	Even	more	disturbing	for	its	practical,	and	more	intriguing	for	its	biological	implications,	is	the	finding	that,	under	conditions	of
cellular	stress,	the	changes	in	proteome	composition	hardly	depend	on	the	nature	of	the	stress.
How	does	the	circulating	concentration	of	current	and	perspective	disease	markers	compare	with	that	of	other	proteins	in	plasma/serum?
Fig.	1	–	—	redrawn	from	[1]	–	—	provides	an	overview	on	the	quantitative	relationships	among	the	various	classes	of	proteins	within	plasma/serum	proteome.	The	overall	dynamic	range	for	their	concentrations
exceeds	1010-fold.	The	range	associated	with	proteins	secreted	continuously,	if	at	a	varying	rate,	in	blood	(e.g.	binding/transport	proteins,	protease	inhibitors,	coagulation	factors,	immunoglobulins)	is	wider	than	105
fold,	that	for	proteins	discontinuously	secreted	in	blood	(as	long-range	extracellular	effectors	e.g.	hormones	and	cytokines)	is	narrower	than	102-fold.	The	remaining	>		103-fold	corresponds	to	the	concentration	range
for	proteins	not	targeted	for	secretion	but	leaking	from	tissues	either	as	intact	molecules	or	as	proteolytic	fragments.
Proteins	leaking	from	tissues	would	become	major	components	of	a	sample	only	after	the	removal	of	hepatocyte	and	plasma	cell	secretion	products,	which	are	10‐−	3‐–10‐−	6	times	more	abundant.	The	subtraction
of	albumin	alone	results	in	the	removal	of	50%	of	the	total	proteins:	while	outstanding	per	se,	such	an	achievement	is	still	inadequate	to	meet	the	requirement	for	trace	component	enrichment.	A	suitable	protocol	using
the	depletion	approach	demands	a	much	more	extensive	cut	of	(all)	major	proteins.	One	way	to	meet	this	requirement	is	through	the	use	of	immunoaffinity	resins;	some	are	marketed,	which	are	able	to	bind	high-	or
medium-abundance	plasma/serum	components,	resulting	in	the	depletion	of	up	to	99%	of	the	total	proteins.
2.2	Without	major	plasma/serum	proteins
2.1.2.1	How	to	remove	major	plasma/serum	proteins
2.1.1.2.1.1	Removing	albumin
From	the	above,	 removing	albumin	alone	 from	plasma/serum,	and	 from	all	biological	 fluids	 that	derive	 from	plasma/serum	 (e.g.	 urine	and	CSF),	definitely	 falls	 short	of	 significantly	enriching	 the	 samples	 in	 low-abundance
proteins.	Still,	some	specific	indications	exist	for	this	procedure.	The	Mr	of	albumin	is	close	to	that	of	many	other	plasma/serum	components	so	the	already	low	resolution	by	mass	afforded	by	1DE	electrophoresis	(SDS-PAGE)	is	further
limited	by	the	presence	of	albumin.	The	pI	of	albumin	differs	significantly	from	that	of	other	plasma/serum	proteins	of	like	(and	unlike)	Mr:	accordingly,	in	2DE	with	IEF	under	equilibrium	conditions,	the	spot	of	albumin	is	quite	distinct
from	all	others.	However,	using	standard	protocols	with	ready-made	IPG	strips	for	the	1st	d	run	and	in-gel	sample	reswelling,	some	of	the	albumin	initially	loaded	at	pH		<		pI	erratically	fails	to	focus.	This	results	in	a	horizontal	streak	in
the	low	pH	(anodic)	region,	which	overlaps	acidic	protein	spots,	blurring	their	pattern	and	confusing	their	quantitation.	Cutting	albumin	concentration	also	cuts	such	interference.
Fig.	1	A	chart	of	the	circulating	concentrations	of	different	classes	of	proteins	found	in	plasma/serum.	(Redrawn	from	[1]).
alt-text:	Fig.	1
A	typical	approach	to	remove	only/mainly	albumin	from	plasma/serum	is	through	dye-ligand	pseudoaffinity	chromatography	[2,3]	on	immobilized	triazine	dyes,	most	often	on	Cibacron	Blue	F3-GA	immobilized	to	give	blue	resins.
With	the	presence	of	both	fused	aromatic	rings	and	sulfate	groups,	this	molecule	recapitulates	key	features	of	the	main	physiological	albumin	ligands	(free	fatty	acids	and	bilirubin),	namely	the	coexistence	of	hydrophobic	and	acidic
functions.	However,	the	resemblance	is	broad,	and	similarity	may	be	detected	also	with	such	an	unrelated	metabolite	as	NAD(P).	Indeed,	high	affinity	for	the	blue	columns	is	shared	by	a	whole	class	of	proteins	–	—	the	NAD/NADP-
dependent	enzymes	 –	—	that	 interact	with	 the	 immobilized	dye	 through	 their	Rossman-folded	binding	sites.	More	relevant	 to	plasma/serum	proteins,	 the	properties	of	 the	 immobilized	 ligand	do	contribute	 to	both	 ion	exchange	and
hydrophobic	 interaction.	 As	 a	 result,	 the	 affinity	 of	 individual	 serum	 proteins	 for	 immobilized	 Cibacron	 Blue	 F3-GA	 changes	 with	 ligand	 density	 (in	 different	 commercial	 products)	 as	 well	 as	 with	 pH	 and	 ionic	 strength	 of	 the
chromatographic	buffer,	whether	under	steady	or	dynamic	conditions	(incubation,	flow)	[4,5].	Moreover,	 the	affinity	of	albumin	 itself	 for	the	 immobilized	dyes	extensively	varies	depending	on	the	species	[6],	being	very	high	for	the
human	protein	but	 from	 lower	 to	much	 lower	 for	many	of	 its	animal	homologs.	Accordingly,	 it	 is	difficult	 to	quantitatively	 remove	albumin	 (from	human	and	even	more	 from	animal	 specimens)	without	carrying	along	other	 serum
proteins;	 for	 instance,	under	most	conditions,	 lipoproteins/apolipoproteins	are	heavily	depleted	as	well.	A	high-salt	buffer	 is	 required	 to	 sharpen	binding	selectivity;	as	 such,	without	desalting,	 the	 flow-through	 from	 the	adsorption
cartridge/column	is	not	directly	suitable	for	loading	in	IEF.	An	assessment	of	dye-ligand	chromatography	in	connection	with	plasma	proteomics	may	be	found	in	[7].	In	a	reverse	perspective	to	depletion,	a	hydroxyethylthioethyl	ester
adducted	tripeptide	produced	by	pronase	digestion	of	albumin	was	used	as	quantitative	biomarker	for	the	diagnosis	of	human	exposure	to	sulfur	mustard;	sample	enrichment	in	human	serum	albumin	by	dye-ligand	chromatography	was
instrumental	to	improve	the	performance	of	the	test	[8].
Mentioning	salts	in	the	previous	paragraph	reminds	a	low-tech,	old-time	approach	for	separating/removing	albumin	from	other	serum	proteins,	i.e.	ammonium	sulfate	precipitation.	Albumin	is	the	only	major	protein	soluble	at
50%	saturation	of	the	chaotrope	while	its	quantitative	precipitation	calls	for	100%	saturation.	As	exemplified	by	a	comparison	of	immunoglobulin	solubility	[9],	species-specificity	sets	the	conditions	for	salting-out	plasma/serum	proteins.
Indeed,	both	the	depletion	of	high-abundance	components	(from	rat	serum	[10])	and	the	fractional	precipitation	of	(human)	plasma	proteome	with	ammonium	sulfate	(attaining	10%,	20%,	25%,	30%,	35%,	40%,	45%,	50%,	and	55%	salt
concentrations	[11])	have	been	recently	explored	as	preliminary	steps	before	2DE	analysis.
Another	chemical	depletion	method	is	based	on	sequential	protein	precipitations	steps.	DTT	(50		mM)	promotes	the	precipitation	of	proteins	rich	in	disulfide	bonds,	with	the	formation	of	a	viscous	precipitate,	mainly	containing
albumin;	the	addition	with	sonication	of	2	vol	of	water	and	4.5	vol	of	acetonitrile	to	the	supernatant	results	in	the	precipitation	of	alpha-2-macroglobulin,	transferrin,	complement	3alpha	(C3),	and	immunoglobulins.	The	depleted	sample
in	the	second	supernatant	may	be	used	in	proteomics	experiments	(Fig.	2)	after	evaporation	of	the	solvent	to	dryness	[12].
Still	a	different	type	of	precipitation	procedure	is	described	in	[13]:	at	pH (pH	(no	Italics))		4.2,	salt	removal	from	serum	(human,	bovine,	or	porcine	specimens	alike)	reproducibly	results	in	the	precipitation	of	albumin	and	other
high	abundance	proteins	(immunoglobulins,	apolipoprotein	A-I,	transferrin,	alpha-2-HS-glycoprotein,	hemopexin,	vitamin	D (vitamin	D	(no	Italics))-binding	protein,	serpin	A3‐–5,	complement	factor	B).
For	some	specific	applications,	excluding	albumin	and	some	other	major	plasma/serum	proteins	either	from	analysis	or	from	detection	after	2DE	may	be	obtained	through	simple	procedures	relying	on	differences	in	Mr.	For
instance,	 in	an	 investigation	on	(human)	amniotic	 fluid	 focused	on	 low-Mr	proteins	and	on	proteolytic	 fragments	 from	high-Mr	components,	we	processed	proteins	 (concentrated	by	 freeze-drying)	 through	two	steps	of	size-exclusion
chromatography	(gel	filtration	on	a	Sephadex	G100	column)	before	the	electrophoretic	analysis	[14].	On	(rat)	serum,	we	have	demonstrated	the	feasibility	of	a	controlled	overloading	followed	by	staining	the	upper	half	of	the	2ndd	slab
Fig.	2	2DE	comparing	the	different	protein	profiles	of	untreated	human	serum	and	of	serum	depleted	according	to	the	sequential	method	in	[12].	Protein	landmarks	are	identified	in	each	map.
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with	Coomassie,	 the	 lower	half	with	 silver	nitrate,	 to	compensate	 for	 the	uneven	abundance	of	higher	and	 lower	Mr	proteins	 in	 the	sample	 [15].	Another	way	 to	partition	proteins	on	 the	basis	 of	 their	 size	 is	 through	 (centrifugal)
ultrafiltration	(with	MWCO	at	30,000),	under	solvent	conditions	(25		mM	NH4HCO3,	pH		8.2,	20%	(v/v)	acetonitrile)	that	hinder	protein-protein	interactions	[16].	In	the	referred	work,	the	authors	did	not	further	fractionate	the	collected
proteins	but	treated	the	whole	low- Mr	filtrate	with	trypsin	and	analyzed	the	resulting	peptides	by	SELDI.
None	of	the	above	procedures	actually	provides	for	strict	selectivity	between	albumin	and	the	other	plasma/serum	components	because	the	fractionation	criteria	rely	on	properties	shared	to	different	extent	by	many/all	proteins,
i.e.	on	quantitative	rather	than	on	qualitative	differences.	An	all-or-none	interaction	may	be	expected	instead	with	such	a	biospecific	device/reagent	as	an	immunoaffinity	resin.	Some	products	are	commercially	available	(e.g.	an	agarose
slurry	with	immobilized	anti-albumin	antibodies,	from	Sartorius),	others	may	be	laboratory-prepared	from	CNBr-	or	Protein	A-Sepharose	gel.	Experimental	evidence	however	shows	that,	together	with	albumin,	a	number	of	proteins	are
bound	to,	and	may	be	released	from,	an	anti-albumin	resin	after	plasma/serum	immunodepletion	(Table	1);	their	ensemble	has	been	given	the	name	of	albuminome	[17].	The	use	of	different	commercial	products	results	in	the	co-binding
of	a	different	assortment	of	non-albumin	proteins	[18].	Albuminome	composition	has	been	assessed	also	through	complementary	approaches.	In	one,	human	albumin	was	immobilized	to	a	solid	activated	immunoaffinity	support	via	a
coupling	reaction.	After	incubating	the	resin	in	a	serum	dilution	and	extensive	washing,	tightly	interacting	proteins	were	eluted	with	a	chaotropic	solution	and	identified	[19].	In	another,	the	supernatant	from	42%	ethanol/100	mM	NaC
precipitation	 on	 IgG-depleted	 serum	was	 processed	 though	 size	 exclusion	 chromatography	 and	 proteins	 co-eluting	 with	 albumin	 were	 assessed	 [17].	 All	 the	 identified	 proteins	 are	 assumed	 to	 interact	 with	 albumin	 in	 vitro	 as	 a
counterpart	 of	 their	 interaction	 in	 vivo;	 accordingly,	 their	 changes	 have	 been	 investigated	 as	 biomarkers	 of	 liver	 disease	 (hepatitis	 C	 virus-related	 cirrhosis,	 small	 unifocal	 hepatocellular	 carcinomas	 and	 advanced	 hepatocellular
carcinomas)	[20].
Table	1	Albuminome	components	[17].
alt-text:	Table	1
Intact	proteins
Apolipo protein	A-II
Apolipo protein	A-IV
Apolipo protein	C-II
Apolipo protein	C-III
Ceruloplasmin
Clusterin
Complement	component	1	inhibitor
Haptoglobin
Hemoglobin,	alpha	chain
Hemoglobin,	beta	chain
Hemopexin
Leucine-rich	alpha-2-glycoprotein
Transferrin
Transthyretin
Vitamin	D-binding	protein
Zinc	alpha-2-glycoprotein
Protein	fragments
Carboxypeptidase	B2
Complement	component	C4
Hornerin
Inter-alpha-trypsin	inhibitor	heavy	chain	H4
Kininogen
Paraoxonase	1
Peptidoglycan	recognition	protein	2
Plasminogen
2.1.2.2.1.2	Removing	major	plasma/serum	proteins
In	agreement	with	the	arguments	in	Section	1,	removing	most/all	major	proteins	from	plasma/serum	is	a	sounder	approach	than	removing	albumin	alone	to	increase	the	sensitivity	of	proteomics	protocols	and	to	extend	detection
and	quantitation	towards	such	minor	components	as	tissue	leakage	proteins.	This	step	is	expected	to	improve	the	resolution	on	2DE	gels	by	enabling	visualization	of	proteins	that	migrate	together	with,	or	close	to,	the	high-abundance
proteins	and	by	increasing	the	load	in	the	least	abundant	components.
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An	attempt	to	exploit,	to	this	aim,	conventional	affinity	procedures	in	the	analysis	of	rat	plasma	can	be	found	in	[21].	The	authors	computed	the	average	hydrophobicity	of	the	major	proteins	in	this	specimen	(N		=		56)	and	sorted
them	in	classes	through	cluster	analysis.	The	high-abundance	proteins	turned	out	to	belong	to	the	medium-hydrophobicity	class,	therefore	hydrophobic	interaction	chromatography	(HIC)	was	rationally	designed	to	deplete	them	from
plasma.	Indeed,	when	applied	before	2DE,	HIC	permits	to	detect	twice	as	many	spots	as	immunoaffinity	depletion	of	albumin	(above).
A	targeted	instead	of	a	broad	approach	implies	molecular	recognition	of	each	of	the	components	to	be	removed,	which	is	feasible	through	immunoadsorption.	A	number	of	proposals	have	been	made	for	laboratory-made	as	well
as	commercial	products	devised	to	bind	a	variable	number	of	plasma/serum	proteins	(N		=		6‐–20),	both	of	human	and	rodent	origin.	The	major	advantage	of	such	devices	is	of	course	the	expected	specificity	of	their	interaction;	the	major
drawback	lies	in	their	extremely	high	cost.	Typically,	for	this	application,	IgYs	[22]	directed	against	plasma/serum	proteins	are	raised	in	hens	during	the	laying	period	and	purified	from	eggs	(structure	in	Fig.	3).	Production	of	IgYs	is
minimally	invasive	on	the	immunized	poultry,	which	complies	with	the	current	guidelines	on	animal	welfare.	Depending	on	the	antigen,	Ig	titer	development	in	chicken	may	compare	more	or	less	favorably	with	rabbits	or	mice.	Chicken
Igs	are	clearly	superior	to	rabbit	Igs	 in	terms	of	epitope	recognition	when	the	antigen	is	a	protein	of	mammalian	origin,	whether	human	or	animal.	Such	an	advantage	in	terms	of	higher	specificity/lower	cross-reactivity	and	higher
sensitivity	 is	 obviously	 connected	 with	 the	 higher	 phylogenetic	 distance	 between	 self	 and	 immunizing	 non-self	 in	 chicken	 than	 in	 mammals.	 Among	 the	 commercial	 products,	 it	 is	 worth	 mentioning	 those	 from	 Agilent
(https://www.agilent.com/),	 from	R&D	Systems	(https://www.rndsystems.com/)	and	 from	Sigma	(http://www.sigmaaldrich.com/).	They	 include	 two	classes	of	depletion	columns:	one	 targeting	12	or	14	of	 the	high-abundance	proteins,
another	the	middle-abundance	proteins;	the	polyclonal	polyspecific	antibodies	for	the	latter	are	obtained	through	immunization	with	the	flow-through	from	the	former.	The	sequential	use	of	both	columns	is	intended	to	leave	in	solution
only	low-abundance	proteins.
A	 related	approach	 to	 ‘ultradepletion’	 of	 human	plasma	was	put	 to	 the	 test	 by	 fractionating	plasma	with	dual	 ion	 exchange	 columns,	 producing	polyclonal	 IgY	 against	 each	 fraction	 and	using	 the	purified	 antibodies	 in	 an
immunodepletion	column.	A	total	of	165	non-redundant	proteins	were	identified	after	depletion;	of	these,	38	had	not	previously	been	identified	in	non-depleted	plasma	[23].
Camelids	produce	functional	antibodies	devoid	of	light	chains;	antigens	are	bound	by	the	N-terminal	variable	domain	of	the	heavy	chain	(see	Fig.	3).	The	corresponding	single-domain	antibody	fragments	(VHHs	or	nanobodies,	in
Fig.	3)	are	fully	capable	of	antigen	binding,	with	affinities	comparable	to	conventional	antibodies.	VHHs	are	efficiently	produced	in	Saccharomyces	cerevisiae.	With	their	high	stability	and	solubility,	these	affinity	reagents	have	several
advantages	 for	biotechnological	applications	 [24].	One	commercial	device	using	 them	to	capture	14	high-abundance	proteins	 is	produced	by	BAC/Bionity	 (http://www.bionity.com/en/companies/15295/bac-b-v.html).	An	example	of	 its
application	may	be	found	in	[25]	(Fig.	4):	removal	of	high-abundance	proteins	is	efficient	and	enrichment	of	low-abundance	proteins	appears	reproducible	from	run	to	run.
Fig.	3	Overview	on	the	structure	of	immunoglobulins	of	different	animal	origin.
alt-text:	Fig.	3
Due	to	the	complexity	of	the	immunological	approach,	several	reports	have	been	devoted	to	the	assessment	of	a	number	of	issues.	The	efficiency	of	immunosubtraction	was	first	evaluated	for	devices	meant	to	remove	6	high-
abundance	proteins	(albumin,	IgG,	IgA,	transferrin,	alpha-1-antitrypsin,	and	haptoglobin),	comparing	the	2DE	pattern	of	serum	before	and	after	removal	of	these	proteins.	One	paper	rated	the	yield	through	the	number	of	detectable
spots:	with	sample	treatment,	the	count	grew	from	approximately	850	to	over	1500,	with	a	76%	increase	[26].	In	another	paper	a	criterion	for	quantitative	comparison	was	identified	in	the	number	of	matched	spots	(applying	an	image
analysis	software	to	the	2DE	patterns	of	several	replicates);	the	matches	totaled	197	before	and	317	after	depletion,	with	an	increase	of	61%	[27]	(Fig.	5).
The	next	issue	to	be	addressed	was	the	cost-effectiveness	of	devices	meant	to	deplete	from	plasma/serum	an	increasing	number	of	abundant	proteins.	With	a	title	asking:	The	more,	the	better?	[28],	a	paper	tries	to	provide	an
answer	to	this	question	by	comparing	the	results	obtained	after	depleting	1	(albumin),	6	(albumin,	IgG,	IgA,	transferrin,	alpha-1-antitrypsin,	and	haptoglobin,	see	above),	12	(the	previous	plus	apo	A-I	and	-II,	α1-acid	glycoprotein,	alpha-2-
macroglobulin,	fibrinogen,	IgM)	or	20	proteins	(the	previous	plus	IgD,	ceruloplasmin,	apo	B,	complement	C1q,	C3,	C4,	plasminogen,	and	transthyretin).	After	analysis	by	1DE	and	2DE	and	SELDI–TOF,	the	outcome	is	not	univocal.	The
gain	is	substantial	removing	12	proteins	instead	of	6,	limited	removing	20	proteins	instead	of	12.	As	already	mentioned	for	albumin	and	its	albuminome,	while	adsorbed	under	non-denaturing	conditions	the	immunocaptured	proteins
remain	associated	with	a	whole	 range	of	peptides	and	proteins,	which	are	 removed	alongside	 (off-target	 effects)	 (Fig.	6).	A	 largely	 similar	 experimental	 design	was	 implemented	 in	 another	paper	 [29].	 In	 this	 case,	 the	 systematic
comparison	 involved	 the	 immunodepletion	of	6,	14	 (the	 two	extra	proteins	bound	vs	the	12	above	are	C3	and	 transthyretin),	 or	20	proteins;	 the	analytical	procedures	 included	both	 top-down	 (2D-DIGE)	and	bottom-up	 (LC-MS/MS)
approaches.	Using	the	combination	1-DE	–	–LC-MS/MS,	the	number	of	Z2	unique	peptides	rose	from	159	in	unfractionated	serum	to	301	following	depletion	of	20	proteins.	When	comparing	the	results	after	immunoadsorption	of	either
Fig.	4	Relative	abundance	of	proteins	identified	in	untreated	plasma	and	in	the	flow-through	fraction	of	an	immunoadsorption	column	targeting	14	major	plasma	components	(bold).	(Redrawn	from	[25]).
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Fig.	5	2DE	comparing	the	different	protein	profiles	of	untreated	human	serum	and	of	serum	immunodepleted	in	six	high-abundance	proteins	(albumin,	IgG,	IgA,	alpha-1-antitrypsin,	transferrin,	and	haptoglobin).	(From	[27]).
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14	 or	 20	 proteins,	 additional	 spots	 were	 seen	 in	 2DE	 but	most	 of	 them	were	 isoforms	 of	 already	 detected	 proteins;	moreover,	 a	 greater	 run-to-run	 variability	 was	 observed	 in	 LC-MS/MS	 after	more	 extensive	 depletion	 (median
%CV	 	=	 	30.9	vs	18.2%).	The	removal	of	either	6	or	14	abundant	components	was	tested	also	on	the	proteins	of	such	peculiar	specimens	as	the	mechanically	induced	skin	suction	blisters,	whose	fluid	may	serve	as	model	sample	for
dermatological	diseases	[30,31]	(Fig.	7).	Analysis	of	the	tryptic	digests	by	2D-LC	(reversed-phase	chromatography	at	high	and	low	pH	after	iTRAQ	derivatization)	associated	the	depletion	of	the	top	14	components	with	a	lower	efficiency
on	the	target	proteins,	yet	a	higher	enrichment	factor,	a	higher	number	of	identified	protein	groups,	an	improved	dynamic	range	and	a	higher	loading	capacity	[31].	Finally,	from	a	further	paper	[32],	we	like	to	quote	quantitative	data	on
the	binding	properties	of	the	Sigma	resins	meant	to	deplete	14	high-abundance	and	a	number	of	medium-abundance	plasma/serum	components:	their	use	removes	at	least	155	proteins,	38%	of	the	plasma	proteome	in	protein	number
and	94%	of	plasma	protein	in	mass.	The	authors	question	on	the	weakness	of	such	extreme	immunodepletion (split	line	at	immuno-depletion	(see	pdf))	procedure	in	front	of	even	slight	variations	in	inter-assay	binding	efficiency:	they	argue
that	the	proteins	associated	with	the	highest	percentage	immunodepletion	are	also	at	the	highest	risk	of	being	identified	as	false-positives	in	differential	proteomic	studies.
Fig.	6	2DE	of	untreated	serum	vs	the	unbound	fractions	collected	after	depletion	of	1,	6,	12	and	20	major	serum	proteins	using	commercial	columns	(Table	1).	A	fixed	amount	of	protein	(50		μg)	was	analyzed	in	all	maps.	(From	[28]).
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Fig.	7	Scatter	plot	of	Log10	iTRAQ	ratios	vs	Log10	average	intensities	for	all	peptide-spectrum	matches.	Blue	circles	correspond	to	the	6	most	abundant	proteins	(albumin,	IgG,	IgA,	transferring,	haptoglobin,	alpha-1-antitrypsin),	and	red	circles	include	the	additional	7−–14	most
As	a	last	line,	similar	to	albuminome,	the	term	depletome	has	been	introduced	to	refer	to	the	off-target	immunosubtracted	proteins	(see	above).
2.2.2.2	How	to	enrich	minor	plasma/serum	proteins
An	opposite	perspective	to	depletion	of	high-abundance	proteins	from	plasma/serum	is	the	enrichment	of	 low-abundance	ones	through	an	increase	of	their	relative	concentration;	such	a	compression	of	the	dynamic	range	is
expected	to	provide	a	deeper	proteome	profiling.	This	technology	was	described	by	the	inventors	as	“protein	equalization”	and	its	effect	as	approaching	a	"“democratic	proteome"”	[33].	The	enrichment	procedure	is	based	on	a	specific
and	saturable	interaction	of	proteins	to	a	high	diversity	of	binding	sites	exposed	on	chromatographic	beads.	The	combinatorial	ligand	library	is	made	up	of	dozens	of	millions	of	hexapeptides	capable	of	interacting	with	most,	if	not	all,
proteins	in	any	given	proteome	[34,35]	(Supplementary	Figs.	1	and	2).	BioRad	(http://www.bio-rad.com/)	markets	the	corresponding	commercial	kit,	ProteoMiner,	together	with	4	elution	reagents	meant	to	sequentially	recover	proteins
on	 the	basis	of	different	properties,	 in	a	 format	compatible	with	analysis	by	SELDI.	Differential	elution	under	native	conditions	may	be	achieved	by	changing	 the	pH	of	 the	buffer	 [36]	or	by	using	a	mixture	of	charged	aminoacids
(150		mM	Lys,	Arg,	Asp	and	Glu)	[37].	Elution	of	all	bound	proteins	under	denaturing	conditions	is	made	possible	by	boiling	the	beads	in	SDS	[38,39];	precipitation	with	acetonitrile	then	provides	for	the	highest	protein	recovery	yield	and
the	best	2DE	spot	pattern	[40].
The	conceptual	background	to	the	peptide	ligand	library	capture	is	a	saturation	effect:	all	the	proteins	present	in	the	starting	sample	in	concentrations	high	enough	to	overload	their	interaction	sites	on	the	beads	should	be
bound	in	equal	amounts,	the	excess	being	discarded	with	the	flow-through.	After	stripping	the	bound	proteins	from	the	resin,	the	concentration	of	the	higher-abundance	proteins	should	be	equalized	in	the	eluted	fraction.	Conversely,	the
proteins	present	in	the	starting	sample	in	concentrations	too	low	to	overload	their	interaction	sites	on	the	beads	should	be	quantitatively	bound.	Accordingly,	the	differences	among	samples	should	be	intentionally	abolished	(or	at	least
reduced)	for	higher-abundance	and	preserved	for	lower-abundance	proteins.	A	test	of	the	quantitative	performance	of	the	capture	beads	shows	an	average	variability	around	10%	in	the	amount	of	the	isolated	proteins,	independent	of
their	initial	abundance.	No	normalization	effect	is	in	fact	observed	but,	depending	on	the	protein-to-bead	ratio,	specific	sets	of	proteins	are	either	enriched	or	depleted	vs	the	starting	whole	proteome	[43]	(Supplementary	Fig.	3).	All
reports	that	evaluate	the	performance	of	the	protein	enrichment	strategy	[44]	or	compare	it	to	depletion	protocols	[45]	acknowledge	the	expected	compression	of	the	dynamic	range	of	serum	protein	concentrations.
To	further	reduce	sample	complexity,	equalization	has	been	combined	with	additional	chromatographic	steps	on	IMAC	and	RP	columns	(tandem	monolithic	columns	with	surface-bound	iminodiacetic	acid	ligands	saturated	with
Zn2	+,	Ni2	+	and	Cu2	+	connected	to	a	reversed-phase	column	packed	with	polystyrene	divinyl	benzene	beads)	[46].	An	alternative	to	the	hexapeptide	ligands	has	been	proposed	in	the	form	of	single	chain	variable	fragment	displaying	M13
phage	library	[47].	Both	immobilization	on	beads	and	elution	of	bound	proteins	require	specific	precautions	not	to	interfere	with	the	structure	of	the	phage;	the	number	of	proteins	identified	from	human	serum	with	such	an	enrichment
procedure	is	twice	as	high	as	from	the	untreated	sample.
The	enrichment	procedure	may	be	applied	to	any	kind	of	sample	of	vegetal	or	animal	origin.	Focusing	on	human	specimens,	plasma/serum	has	been	used	most	often	both	when	setting	up	the	procedures	and	when	analyzing
actual	samples	for	marker	discovery.	However,	also	other	body	fluids	have	been	processed	this	way,	including	cerebrospinal	fluid	[48],	milk/milk	whey	[49,50],	saliva	[51],	seminal	plasma	[52],	artificial	peritoneal	dialysis	effluents	[53]
synovial	fluid	[54].
The	pathological	states	mainly	investigated	were	neoplasias	(pancreas	[55],	lung	in	never-smokers	[56]	and	of	the	non-small	cell	type	[57,58])	and	infections	(hepatitis	B-associated	liver	cirrhosis	[59],	HIV-1/HCV	mono-	and	co-
infection	[60],	invasive	aspergillosis	–	—	in	a	mouse	model	[61]).	Two	further	topics	of	peculiar	interest	addressed	with	this	technique	were	the	changes	occurring	in	serum	with	gestational	ages	(for	infants	with	intrauterine	growth
restriction	[62])	and	those	occurring	under	extreme	physical	stress	[63].
An	alternative	enrichment	approach	based	on	physicochemical	properties	of	the	proteins	rather	than	on	their	binding	affinities	is	being	proposed	in	[64].	This	method,	which	targets	hydrophobic	proteins,	consists	of	a	phase
separation	with	Triton	X-114.	The	detergent-rich	phase	is	collected	after	raising	the	temperature	to	above	the	cloud	point,	then	diluted	at	a	temperature	below	the	cloud	point	and	concentrated	by	a	TCA-acetone	precipitation	step.	In	a
comparison	with	analysis	on	whole	serum	and	on	serum	processed	through	albumin	and	IgG	immunodepletion	and	 protein	enrichment	on	hexapeptide	resin,	 the	alternative	approach	allowed	to	recognize	statistical	significance	of
differences	between	control	and	test	animals	(pigs	exposed	to	feed	supplementation	with	sub	therapeutic	levels	of	oxytetracycline)	for	three	hydrophobic	proteins,	namely	apolipoprotein	F,	clusterin	and	paraoxonase.
3.3	With	major	plasma/serum	proteins:	How	to	deal	with	whole	plasma/serum
3.1.3.1	Strategies	in	proteomics
All	we	have	presented	so	far	shares	a	perspective:	differences	in	minor	components	are	sought	in	plasma/serum	after	simplifying	the	composition	of	the	sample.	Removing	major	components	is	the	primary	strategy;	further
abundant	proteins	(IgM,	alpha-2-macroglobulin,	fibrinogen,	complement	C3,	alpha-1-acid	glycoprotein,	apolipoprotein	A-I/II	(HDL),	and	apolipoprotein	B	(LDL)).	(From	[31]).
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simplification	may	be	obtained	with	any	fractionation	procedure	while	the	final	resolution	into	sizeable	analytical	units	 is	obtained	with	1D-	or,	more	usually,	2D-procedures,	either	electrophoretic	or	chromatographic.	Investigations
along	this	line	are	not	guided	by	previous	knowledge:	statistical	significance	of	differences	in	abundance	is	the	only	selection	criterion.	In	this	sense,	these	investigations	fully	comply	with	the	definition	of	proteomics	as	an	unbiased
qualitative	and	quantitative	evaluation	of	all	protein	components	in	a	given	sample	–	—	sample	in	this	case	being	human	plasma/serum.
To	overcome	the	difficulties	along	this	track,	more	and	more	often	the	proteomic	investigation	on	human	pathologies	is	being	moved	from	plasma/serum	to	tissues.	Proteins	whose	concentration	is	significantly	altered	under	the
test	vs	the	reference	conditions	are	then	measured	in	plasma/serum	of	the	same	subjects	to	verify	whether	the	components	of	 interest	are	present	at	a	 level	adequate	for	reliable	quantitation.	When	this	 is	the	case,	the	circulating
concentrations	are	evaluated	and	statistical	significance	of	differences	is	finally	assessed.
However,	human	specimens	other	than	few	body	fluids	require	invasive	procedures	for	their	procurement,	which	are	often	neither	practicable	nor	ethically	acceptable.	Moreover,	due	to	genetic	and	environmental	influences,
sampling	conditions	from	human	subjects	are	seldom	comparable,	which	increases	biological	diversity	in	any	test	population.	For	these	reasons,	in	many	cases,	the	simple	scheme	above	is	better	extended	from	a	two-	to	a	multistep
procedure.	Proteomic	analysis	at	the	tissue	level	is	carried	out	on	animal	models	of	disease	vs	relevant	controls.	Differential	proteins	are	then	sought	in	human	tissue	sections,	to	verify	whether	in	the	human	species	the	same	differences
in	abundance	between	test	and	control	samples	are	present	as	in	the	animal	model.	Only	after	this	check	the	quantitation	on	human	plasmas/sera	is	eventually	carried	out	for	the	putative	biomarkers.
While	the	discovery	phase	of	this	alternative	strategy	implies	tools	and	procedures	typical	of	proteomics,	the	validation	phase	usually	completely	relies	on	immunological	reagents.	The	quality	of	the	latter	is	crucial	in	the	whole
process	but	producing/screening	high-specificity	high-affinity	antibodies,	whether	polyclonal	or	monoclonal,	is	not	an	easy	task.
Overviews	on	integrated	strategies	for	biomarker	discovery	and	validation	have	been	published	(e.g.	[65]).	All	of	these	aspects	are	dealt	with,	through	relevant	examples,	in	the	following	sections.
3.1.1.3.1.1	Reference	immunological	reagents
The	limited	number	of	available	specific	antibodies	in	spite	of	a	multitude	of	efforts	in	the	academic	and	industrial	sectors	led	the	Human	Proteome	Organization	(HUPO)	to	endorse	antibody-based	proteomics	programs	involving
the	systematic	generation	of	antibodies	for	use	in	functional	exploration	of	the	human	proteome	with	a	high-throughput	approach	[66,67].
This	endeavor	has	been	given	the	name	of	Human	Protein	Atlas	(http://www.proteinatlas.org/about);	it	was	started	at	the	Royal	Institute	of	Technology,	Sweden,	in	2003	and	is	funded	by	the	non-profit	organization	Knut	and	Alice
Wallenberg	Foundation.	Updates	on	the	program	achievements	are	since	published	on	a	regular	basis	(e.g.	[68,69]).
The	in-house	antibody	production	process	begins	with	a	bioinformatics	analysis	of	the	protein-coding	part	of	the	genome.	For	every	protein,	the	amino	acid	sequence	is	compared	to	all	other	putative	protein-coding	genes	to
identify	 a	 stretch	of	50‐–150	amino	acids	 that	has	 as	 low	homology	as	possible	with	 respect	 to	 all	 other	proteins.	These	 sequences	 are	 then	 cloned	 from	cDNA	 libraries	using	 specifically	designed	primers	 and	 transformed	 into	E.
coliEscherichia	coli	bacteria	that	produce	the	corresponding	peptide	chain	(protein	epitope	signature	tag	or	PrEST).	The	PrEST	is	used	for	various	applications	including	immunization	to	produce	antibodies,	and	for	affinity	purifying	the
polyclonal	antisera	to	make	them	strictly	monospecific.	Numerous	quality	assurance	and	validation	steps	are	performed	to	eventually	certify	the	antibodies.	The	same	validation	protocol	is	applied	also	to	commercial	products	and	to
antibodies	prepared	by	collaborating	institutions.
By	copying	in	the	above	paragraphs	most	of	the	basic	information	about	the	pipeline	of	antibody	production	summarized	in	the	Atlas	web	site,	we	want	to	emphasize	that,	in	order	for	the	quantitative	results	from	in	solution	or
from	on	membrane	immunodetection	procedures	to	be	meaningful,	the	quality	of	the	immunological	reagents	must	be	certified	through	a	complex	and	stringent	procedure	(typically	by	external	bodies)	and	the	calibration	curves	for	the
assay	be	carefully	built	(in	house).	Sometimes	the	differential	item	corresponds	to	just	one	of	a	number	of	species	deriving	from	a	single	polypeptide	through	differential	PTM	processing	(see	Section	4.1).	In	these	cases	the	copy	number
per	cell	of	 the	protein	 (all	species)	 is	affected	much	 less	 than	that	of	 the	 individual	species;	a	measure	of	 the	protein	as	a	whole,	by	ELISA	or	by	 immunoblotting	after	1DE,	would	 likely	miss	statistically	significant	differences	 (an
exception,	1DE	after	extensive	proteolysis).	Such	cases	can	be	effectively	addressed	only	through	2DE	with	immunoblotting	and	comprehensive	image	analysis.
3.1.2.3.1.2	Reference	data	on	tissue	proteomics
The	baseline	level	of	expression	for	each	individual	protein	in	each	tissue	is	relevant	information	when	changes	under	pathological	conditions	are	evaluated.	Therefore	we	go	on	reporting	basic	information	about	the	Protein	Atlas
project.
Protein	expression	profiles	are	produced	for	each	of	the	certified	antibodies	by	staining	different	standardized	sets	of	biological	samples	from	44	different	normal	human	tissues,	20	different	cancer	types,	46	different	human	cell
lines	and	6	hematopoietic	cell	types	from	patients.	As	of	spring	2016,	proteome	analysis	has	been	carried	out	based	on	25,039	antibodies,	targeting	17,005	unique	proteins	[69];	results	are	available	on	line,	in	a	searchable	web	site
(http://www.proteinatlas.org/about)	that	also	contains	transcriptomics	data	on	the	mRNAs	coding	for	the	same	proteins.	Information	is	divided	into	a	Tissue	Atlas,	a	Subcellular	Atlas,	a	Cell	Line	Atlas	and	a	Cancer	Atlas.
In	detail,	the	tissue	microarrays	for	high-throughput	immunohistochemistry	consists	of	multiple	1-mm	diameter	cores	from	formalin-fixed	paraffin-embedded	tissue	specimens,	arranged	in	a	single	paraffin	block.	Each	block	is
cut	into	200‐–250	sections	to	be	used	for	separate	immunohistochemical	staining	experiments;	processing	several	arrays	under	similar	conditions	sizably	reduces	intra-experimental	variation.	The	stained	slides	are	then	scanned	and
pathologists	annotate	each	core	image	by	scoring	the	intensity	of	immunoreactivity	with	its	cellular	localization	and	by	counting	the	fraction	of	immunostained	cells.
3.1.3.3.1.3	Multistep	experimental	plans
From	the	first	proposals	to	the	most	recent	experiences,	increasing	levels	of	complexity	may	be	found	in	different	experimental	plans,	shifting	between	tissues	and	body	fluids	and	between	human	and	model	animal	specimens.
A	breakthrough	in	this	area	was	the	use	of	xenografts,	i.e.	immune-incompetent	nude	(mutation	in	Foxn1	gene)	or	SCID	(mutation	in	Prkdc	gene)	or	RAG-2/γ(c)KO	(H-2d	RAG2	−/−IL-2Rγ	−/−,	or	RAG2	−/−γc	(gamma	common)−/−
mice	transplanted	with	human	tumor	cells.	Proteins	secreted	(or	shed)	by	the	tumor	can	be	identified	in	mouse	circulation	and	their	human	derivation	confirmed.	The	xenograft	setup	provides	a	much	more	favorable	ratio	of	the	relevant
human	tumor-derived	biomarkers	vs	the	irrelevant	mouse	plasma/serum	protein	background.	Examples	of	this	approach	include	the	following	reports,	in	which	either	established	cell	lines	or	pathological	material	derived	from	individual
cancer	patients	are	grafted.
As	for	the	established	lines,	PC339	cells	provide	a	model	of	androgen-independent	human	prostate	cancer;	tumor-derived	human	nm23/nucleoside-diphosphate	kinase	and	six	human	enzymes	involved	in	glycolysis	were	identified
in	mice	bearing	the	xenograft	 [70].	A	hepatocellular	carcinoma	model	may	be	obtained	by	 injection	of	HCCLM3	cells;	 the	 levels	of	circulating	cytokeratin	19	and	of	 its	 fragment	CYFRA	21-1	were	 found	associated	with	metastasis
potential	[71].	Three	cell	lines	(liposarcoma	[SW872],	osteosarcoma	[KHOS‐
24OS],	 and	 mammary	 adeno-carcinoma	 [MDA-MB-436])	 exist	 in	 two,	 non-angiogenic	 (microscopic,	 dormant	 tumors)	 or	 angiogenic	 (rapidly	 growing	 tumors) 	 phenotypes;	 analysis	 of	 the	 corresponding	 xenografts	 suggested	 that
platelet-associated	platelet	factor-4,	but	not	its	plasma	counterpart,	may	represent	a	potential	biomarker	of	early	tumor	presence	[72].	Grafted	MKN45	gastric	cancer	cells	were	found	to	release	in	mouse	plasma	human	apoA-I;	its	level
was	lower	in	mice	with	large	than	in	those	with	small	tumors	[73].
As	an	example	of	biopsy-derived	cell	lines,	specimens	from	both	human	oral	squamous	cell	carcinomas	and	adjacent	control	tissue	were	transplanted	orthotopically	into	mouse	tongues;	several	proteins	were	found	to	differ	in
concentration	between	control	and	cancer-bearing	mice;	among	these,	EGFR	levels	inversely	correlated	with	the	invasive	phenotype	[74,75].
The	 first	 type	 of	 advance	 from	 the	 above	 scheme	was	 the	 validation	 in	 human	 sera	 of	 the	 findings	 in	 the	 xenograft	mouse	models.	 For	 instance,	 transplant	 of	NPC-TW02	 cells,	 derived	 from	a	 keratinizing	 nasopharyngeal
carcinoma,	resulted	in	elevated	circulating	levels	of	peroxiredoxin	2	and	carbonic	anhydrase	2;	similar	results	came	from	the	analysis	of	plasma	from	nasopharyngeal	carcinoma	patients	[76].	Ninety-seven	proteins	were	identified	in	the
culture	supernatant	of	the	ovarian	cancer	cell	line	SKOV-3.	After	the	cells	were	xenografted	into	the	peritoneal	cavities	of	nude	mice,	three	of	these	proteins	were	detected	in	animal	sera;	one	of	them,	14‐–3-3	zeta,	was	identified	as	a
candidate	biomarker	through	an	ELISA-based	screening	of	clinical	blood	samples.	The	average	serum	levels	of	14‐–3-3	zeta	were	higher	in	patients	with	epithelial	ovarian	cancer	than	with	benign	gynecological	diseases	and	correlated
with	clinical	parameters	of	disease	severity	[77].	Using	a	different	ovarian	cancer	cell	line,	TOV-112D,	more	than	200>	200	human	proteins	were	identified	in	the	xenograft	serum;	three	of	them	(chloride	intracellular	channel	1,	cathepsin
D,	and	peroxiredoxin	6)	were	then	found	elevated	in	sera	from	ovarian	carcinoma	patients	[78].
A	similar	shift	in	plans	applies	to	a	different	type	of	animal	models,	the	genetically	engineered	mice.
Both	sera	and	 tissue	samples	were	compared	 from	Pdx1-Cre	KrasG12D	Ink4a/Arflox/lox	mice	as	models	of	pancreatic	cancer	and	 from	KrasG12D	Ink4a/Arf	 lox/lox	 and	Pdx1-Cre	 Ink4a/Arflox/lox	 control	 animals.	 A	 panel	 of	 five	 proteins
selected	on	the	basis	of	their	increased	level	at	an	early	stage	of	tumor	development	in	the	mouse	(neutrophil	gelatinase-associated	lipocalin,	lithostathine-1-alpha,	regenerating	islet-derived	protein	3-alpha,	metalloproteinase	inhibitor	1,
and	insulin-like	growth	factor-binding	protein	4)	was	tested	in	a	blinded	study	on	26	subjects	with	increased	cancer	risk	(from	the	large	cohort	of	>		18,.000	individuals	enrolled	in	the	Carotene	and	Retinol	Efficacy	Trial,	CARET).	The
panel	discriminated	pancreatic	cancer	cases	from	matched	controls	in	blood	specimens	obtained	between	7	and	13	 	months	prior	to	the	development	of	symptoms	and	clinical	diagnosis	of	pancreatic	cancer	[79].	Plasma	data	from	a
comparison	between	AdenoCre-infected	K-ras/Pten	mice	as	an	ovarian	cancer	model	and	Adeno-empty	injected	controls	were	evaluated	against	evidence	from	three	human	ovarian	cancer	cell	lines	(OVCAR3,	CAOV3,	and	ES2)	and	from
cells	in	the	ascites	fluid	of	an	ovarian	cancer	patient.	A	set	of	proteins	(insulin-like	growth	factor-binding	protein	2,	metalloproteinase	inhibitor	1,	retinoic	acid	receptor	responder	protein	2,	monocyte	differentiation	antigen	CD14,	and
granulin)	were	measured	at	higher	levels	in	pathological	than	in	control	tissues	and	body	fluids,	both	human	and	murine.	The	difference	from	controls	was	significant	from	the	early	stages	of	the	disease	[80].
An	example	not	related	with	cancer	 involves	a	transgenic	mouse	model	with	cardiac-specific	overexpression	of	activated	calcineurin	(CnA),	which	results	 in	severe	cardiac	hypertrophy.	Four	proteins	(myosin	heavy	chain	7,
insulin-like	growth	factor-binding	protein	7,	annexin	A2,	and	desmin)	were	found	significantly	different	in	the	CnA	hearts	compared	to	controls	and	overexpressed	in	proteomic	and	transcriptomic	dataset	of	heart	failure.	Immunological
quantitation	in	mouse	and	human	sera	demonstrated	that	all	four	proteins	increased	between	twofold	and	150-fold	in	heart	failure	[81].
,
3.2.3.2	Procedures	in	proteomics
Both	optimal	and	maximum	load	in	a	separation	procedure	is	a	function	of	the	size	(length,	surface,	or	volume)	of	the	separation	medium	during	its	limiting	step.	In	2DE,	the	volume	of	the	1std	IPG	strip	controls	the	total	amount
of	proteins	to	be	processed	per	test.	Using	standard	ready-made	commercially	available	strips,	the	amount	of	proteins/the	volume	of	whole	(and	as	well	as	of	depleted)	plasma/serum	to	be	run	is	also	standard.
Using	standard	ready-made	commercially	available	IPG	strips	is	the	most	common	procedure	in	IEF	for	practical	reasons	that	include	both	the	ease	of	the	current	simplified	protocols	and	the	reproducibility	of	the	substrate	for
the	separation	procedure,	which	entails	the	reproducibility	of	the	results.	These	obvious	advantages	should	however	be	weighed	against	a	few	disadvantages,	lack	of	flexibility	being	the	most	evident	and	the	most	stringent.
From	the	early	history	of	IPGs	[82]	we	are	accustomed	to	polymerize	our	own	gels,	in	all	kind	of	pH	gradient,	and	to	cut	strips	from	them,	of	all	sizes	and	shapes	[15].	This	makes	it	very	easy	to	load	very	large	volumes	of	whole
serum;	the	only	precaution,	already	recalled	in	2.1.1,	is	to	apply	the	sample	near	the	cathode,	since	running	through	regions	with	pH	lower	than	pI	most	often	results	in	substantial	albumin	streaking,	as	first	demonstrated	by	us	back	in
1985	[83].	Conversely,	exposure	to	acidic	pH	of	much	of	the	albumin	content	of	a	sample	cannot	be	avoided	when	proteins	are	loaded	through	the	in-gel	rehydration	procedure	that	is	customary	with	the	commercial	IPG	strips.
Even	 for	animals	 the	 size	of	 a	mouse	 –	—	few	 tens	 of	 grams	 in	weight	 –	—	tens	 of	microliters	 of	whole	 plasma/serum	are	most	 often	 available	 for	 testing.	 This	 allows	 for	 each	 sample	 to	 be	 analyzed	 under	more	 than	 one
experimental	condition.	Using	2DE,	obvious	variations	 to	 the	basic	procedure	aim	at	 focusing	on	one	or	more	areas	 in	 the	pI/Mr	plane	via	zooming-in	 i.e.	by	narrowing	 the	 range	of	protein	charge	and	mass	 to	be	covered	at	high
resolution.	However,	a	less	frequently	taken	but	highly	effective	alternative	is	to	run	each	sample	both	under	reducing	and	under	non-reducing	conditions.	As	we	have	demonstrated	for	a	number	of	species,	humans	and	animals	as	well,
this	change	in	experimental	protocol	significantly	modifies	the	migration	position	not	only	of	disulfide-associated	multi-chain	assemblies,	which	split	 into	their	constituent	subunits,	but	also	of	disulfide-bridged	single-chain	proteins,
whose	unfolding	in	the	presence	of	SDS	is	restricted	by	the	presence	of	covalent	bonds	[84].
The	following	observations,	 taken	from	[84],	summarize	our	 findings	about	 the	major	serum	proteins	 in	 four	species	–	—	Homo	sapiens	(Fig.	8),	Rattus	norvegicus,	Mus	musculus,	 Bos	 taurus	 –	—	and	 stress	 advantages	 and
disadvantages	of	alternative	procedures.	Under	non-reducing	conditions	albumin	of	all	species	migrates	to	a	much	lower	Mr	than	under	reducing	conditions:	55	vs	68		kDa,	consistent	with	the	presence	of	17		S-S	bonds.	Either	because	of
better	recovery	or	higher	affinity	for	CBB	stain,	the	spot	for	non-reduced	albumin	is	larger	and	darker.	Polymeric	forms	on	top	of	a	diffuse	vertical	streaking	are	also	observed.	Unreduced	conditions	allow	for	the	best	resolution	between
albumin	and	hemopexin	 in	human,	mouse	and	rat	serum	samples.	Albumin	 fragments	are	present	 in	different	amount	 in	various	species.	Where	 they	are	prominent	 (rat	and	mouse	serum)	detection	 is	possible	only	after	 reduction
–	—	which	implies	the	presence	in	rat	and	mouse	circulation	of	a	substantial	amount	of	cleaved	but	undissociated	albumin.
Transferrin	also	contains	a	large	number	of	S-S	bridges	(19)	and	its	Mr	shifts	from	71	to	77		kDa	between	non-reducing	and	reducing	conditions.	Bovine	serum	contains	two	different	molecular	forms	of	transferrin,	which	differ
by	the	presence	or	absence	of	a	C-terminal	peptide	of	about	6		kDa	[85].	The	resolution	between	the	two	is	minimal	under	non-reducing	conditions	but	 increases	on	reduction.	The	charge	microheterogeneity	of	native	transferrin	is
connected	to	both	covalent	post-transcriptional	modifications	(glycosylation,	implying	up	to	8	sialic	acid	residues)	and	non-covalent	interactions	(binding	of	up	to	2	Fe++	ions).	The	susceptibility	to	urea	denaturation	varies	depending	on
iron	saturation	and	redox	status.	The	diferric	protein	is	unaffected	by	urea,	and	in	the	monoferric	transferrin	only	the	iron-free	domain	is	assumed	to	unfold	[86];	in	ovotransferrin,	the	molecule	containing	4		S-S	bridges	is	still	able	to
bind	iron,	and	the	corresponding	complex	doesn't	unfold	in	8		M	urea,	whereas	the	3		S-S	and	2		S-S	proteins	exist	only	as	apoforms	[87].	Accordingly,	more	proteins	species	are	resolved	before	than	after	S-S	reduction.
The	amount	of	immunoglobulins	varies	among	species,	being	much	higher	in	humans	and	Bovidae	than	in	Rodentia.	As	expected,	without	sample	reduction	Igs	form	horizontal	streaks	at	high	Mr	whereas	after	reduction	heavy
and	light	chains	are	resolved	at	lower	Mr.
Fig.	8	2DE	pattern	of	serum	from	a	control	subject	run	under	non	reducing	(left)	vs	reducing	conditions	(right).	Our	unpublished	results.
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Baseline	levels	of	haptoglobin	also	vary	among	species,	being	higher	in	humans	and	mice.	In	these	serum	samples,	alpha	and	beta	chains	are	resolved	after	sample	reduction	but	no	intact	haptoglobin	is	observed	in	the	2DE	map,
probably	as	a	result	of	aggregation.	In	contrast,	in	rat	serum	a	distinct	if	faint	series	of	high	Mr	haptoglobin	spots	is	seen	under	non-reducing	conditions.	Possibly	due	to	their	low	abundance	once	separated,	both	alpha	and	beta	chains
are	hardly	detectable	 in	 rat	 serum	after	 sample	 reduction.	 In	 rats	 and	bovines,	noticeable	 levels	 can	only	be	detected	 in	 case	of	 inflammation	 [88,89].	 In	 addition,	haptoglobin	appears	 in	different	phenotypes	and	polymorphisms,
depending	on	the	species	[90].
Apolipoprotein	A-II	is	a	homodimer	in	humans	and	a	monomeric	protein	in	the	other	species.	Accordingly,	the	Mr	of	apoA-II	in	human	serum	is	twice	as	high	under	non-reducing	than	under	reducing	conditions.
The	most	crowded	area	in	serum	2DE	patterns	is	the	one	where	several	‘alpha-globulins’	migrate	–	—	pI	ca.	4.5‐–6	and	Mr	ca.	50‐–70		kDa.	In	human	and	rat	samples	the	intrinsic	differences	in	pI	and	Mr	between	adjacent	spot
rows	under	reduced	conditions	are	sufficient	for	discrimination	of	all	components	with	minimal	overlaps.	Full-range	IPG	and	SDS-PAGE	are	adequate	for	quantitation	of	all	serum	proteins	and	zooming	is	an	aid,	not	a	requirement,	for
resolution	 in	 the	 ‘alpha-globulin’	 area	of	 these	 species.	With	mouse	 serum	 the	 reduced	proteins	migrate	 in	 closer	proximity,	 and	 zooming	becomes	more	 valuable.	 In	 reduced	bovine	 serum	a	number	of	 proteins	 concentrate	 in	 an
extremely	narrow	Mr	range	while	forming	a	continuum	of	charge	distribution	with	few	sharply	defined	spots:	even	with	specific	PAA	gradients	for	finer	size	resolution	the	discrimination	among	proteins	is	thus	very	poor.
For	all	serum	samples	the	situation	in	terms	of	overall	resolution	over	the	specified	‘alpha-globulin’	area	is	at	least	as	good	under	non-reducing	as	under	reducing	conditions	–	—	and	in	some	cases	it	is	more	favorable	to	run	the
proteins	unreduced	or	partially	reduced.	This	is	especially	the	case	with	bovine	serum:	for	its	analysis	it	seems	appropriate	to	use	a	two-step	strategy,	namely	a	run	under	reducing	conditions	on	a	wide	range	2DE	gel	followed	by	a	run
under	non-reducing	conditions	on	a	narrow-range	2DE	gel	(e.g.	pH	4‐–6	IPG,	SDS-PAGE	on	6‐–12%	PAA).	The	second	step	is	adequate	for	the	evaluation	of	the	‘alpha-globulins’,	the	first	step	for	the	evaluation	of	the	other	proteins	(low
Mr,	or	alkaline	pI).
4.4	Focus	on	major	plasma/serum	proteins
Much	of	what	we	have	described	so	far	has	as	an	explicit	or	implicit	rationale	the	quest	for	optimal	procedures	to	detect	and	quantify	minor	serum	components,	most	of	which	derived	from	peripheral	tissues	as
a	result	of	pathological	events.	In	this	perspective,	major	serum	proteins	are	regarded	as	a	worthless	burden.	In	the	following	we	propose	a	different,	or	at	least	complementary,	view.
The	point	we	want	to	make	is	that	information	provided	by	abundant	proteins	should	not	be	overlooked,	mainly	when	dealing	with	a	poorly	characterized	naturally	occurring	condition	or	with	a	newly	devised
experimental	model.	Ideally,	in	our	opinion,	the	survey	on	whole	plasma/serum	should	always	be	the	first	step	of	a	multistage	investigation,	trying	to	address,	one	after	another,	qualitative	and	quantitative	features	of
different	sets	of	test	proteins	at	increasing	levels	of	resolution.
4.1.4.1	Protein	species
Each	protein	may	 exist	 in	 various	molecular	 forms	 as	 the	 compound	 result	 of	 several	 types	 of	 PTM	 [91].	Changes	 in	 the	 relative	 abundance	 of	 these	 protein	 species	 reflect	 the	 varying	 activity	 of	 the	 enzymes	 involved	 in
alternative	PTM	processing	(two	recent	review	articles	on	this	topic	as	applied	to	e.g.	neurodegeneration	and	autoimmune	disease	are:	[92,93]).	The	activities	of	the	modifying	enzymes	are	in	turn	affected	by	a	number	of	physiological
and	pathological	factors:	data	from	the	assessment	of	individual	protein	species	may	thus	provide	clues	to	the	attendant	conditions.
4.1.1.4.1.1	Proteolysis
Albumin	is	present	in	plasma/serum	in	forms	that	differ	by	size	–	—	proteolytic	fragments	on	the	one	side,	polymers	on	the	other.	The	former	are	detectable	only	under	reducing	conditions,	the	latter	only	under	non-reducing
conditions	(Section	3.2).	In	normal	human	plasma,	albumin	fragments	have	Mr	around	45,	28	and	19		kDa	and	make	up	less	than	2<	2%	of	total	albumin.	The	oxidant	environment	of	the	extracellular	milieu	prevents	fragment	dissociation
to	occur	in	vivo:	indeed,	the	ratio	fragments	vs	intact	albumin	is	not	higher	in	urine	than	in	plasma/serum	samples	from	the	same	subject.
Chymase	 is	 a	 chymotrypsin-type	 serine	 protease	 stored	 in	 the	 intracellular	 granules	 of	mast	 cells	 until	 liberated	 by	 degranulating	 stimuli.	 Proteolysis	 of	 its	 substrates	 is	 part	 of	 the	 inflammatory	 response:	 processing	 of
angiotensin	I	to	angiotensin	II	supports	blood	pressure;	degradation	of	inflammatory	cytokines	and	other	bioactive	peptides	limits	the	spread	of	the	reaction;	activation	of	procollagenase	to	collagenase	contributes	to	extracellular	matrix
remodeling	and	to	resolution	of	tissue	injury	[94,95].	Chymase	recognizes	 in	albumin	the	target	sequence	RETY	to	cleave	 it	at	Y84	and	produce	a	 larger,	ca.	59	 	kDa,	and	a	smaller,	ca.	10	 	kDa,	 fragment	 [96].	However,	 as	 the	 two
fragments	do	not	dissociate	(because	of	the	C75‐
S‐
S‐
C91	 covalent	 bond)	 nicking	 by	 chymase	 has	 no	 influence	 on	 the	 properties	 of	 albumin,	 including	 cation	 binding	 (Cu2	 +	 or	 Zn2	 +)	 at	 a	 site	 near	 the	 cleavage	 point	 [96].	 Accordingly,	 the	 in	 vitro	 demonstration	 of	 anticoagulant
properties	for	S-carboxymethylated	CNBr-fragments	of	albumin	is	unlikely	to	have	any	in	vivo	counterpart,	and	not	only	because	of	the	unphysiological	type	of	cleavage	[97].
A	 peculiar	 type	 of	 nicking	 is	 involved	 in	 the	 antiprotease	mechanism	 of	 serpins,	 as	 exemplified	 by	 alpha-1-antitrypsin.	 A	 protease,	most	 often	 elastase	 from	 granulocytes,	 docks	with	 the	 exposed	 reactive	 loop	 of	 alpha-1-
antitrypsin,	because	its	sequence	and	conformation	resemble	a	model	substrate.	After	cleavage	at	the	‘bait’	peptide	bond	(M358-S359),	the	reactive	loop	rapidly	inserts	within	an	underlying	beta-pleated	sheet	motif	as	an	extra,	central
beta-strand.	In	the	process,	the	catalytic	machinery	of	elastase	is	distorted	and	the	enzyme	cannot	complete	the	catalytic	cycle	and	regenerate	to	the	free,	active	form	from	the	reaction	intermediate	(in	which	elastase	acylates	S359).
The	 thermodynamic	 changes	 associated	 with	 the	 conformational	 rearrangement	 of	 alpha-1-antitrypsin	 from	 a	 metastable	 (S,	 for	 stressed)	 to	 a	 stable	 (R,	 for	 relaxed)	 conformation	 are	 highly	 favorable,	 and	 allow	 the	 coupled,
thermodynamically	unfavorable,	distortion	and	trapping	of	elastase	to	take	place	[98,99].	The	occurrence	of	circulating	elastase–alpha-1-antitrypsin	complexes	has	proven	to	be	a	most	sensitive	 indicator	of	granulocyte	activation	 in
sepsis	and	trauma	[100,101].	As	such	it	has	for	instance	been	evaluated	as	a	marker	of	unwanted	side	effects	of	exogenous	surfactant	replacement	for	immature	preterm	neonates	with	respiratory	distress	syndrome	[102].	Baseline	levels
of	the	complexes	are	around	0.1		μg/mL	to	increase	a	few	folds	during	granulocyte	activation	[103];	their	quantitation	is	made	by	ELISA.
Thyroxine-binding	globulin	(TBG)	is	a	non-inhibitory	serpin.	Cleavage	by	elastase	results	in	the	loss	of	a	4-	to	5-kDa	C-terminal	fragment	and	a	major	conformational	change	that	weakens	the	affinity	for	T4	[104].	The	proteolytic
fragments	are	observed	in	sera	of	septic	patients	[104]	but	also	during	the	rapid	decrease	of	TBG	following	cardiopulmonary	bypass	[105].	The	fall	in	concentration	to	a	mean	level	of	60%	vs	the	preoperative	control	at	12		hoursh	seems
thus	connected	with	the	local	inflammatory	response	to	the	surgical	procedure	and	results	in	the	accumulation	of	free	T4	at	the	inflamed	sites	[105].
We	have	described	ourselves	how	apolipoprotein	A-I	in	HDL	is	a	target	of	the	matrix	metalloproteinases	released	from	activated	macrophages.	The	fragments,	of	26,	22,	14	and	9		kDa	in	size,	result	from	both	N-	and	C-terminal
cleavage	and	dissociate	from	bound	lipids.	HDL3C	(small	pre-beta	HDL)	are	more	extensively	degraded	than	the	other	HDL	subclasses,	with	adverse	effects	on	reverse	cholesterol	transport	in	which	the	smallest	lipoprotein	particles	are
specifically	 involved	 [106].	We	could	detect	 in	vivo	proteolytic	 fragments	of	apolipoprotein	A-I	 in	 some	patients	with	acute	myocardial	 infarction,	 likely	as	a	 result	of	 the	same	activation	events	 that	 in	 these	subjects	 lead	 to	plaque
fissuration	[107].	Moreover,	we	observed	such	fragments	also	after	thrombolysis	with	(recombinant)	tissue-type	plasminogen	activator.	This	therapy	was	an	early	breakthrough	for	the	treatment	of	coronary	occlusion.	Once	percutaneous
coronary	intervention	became	a	feasible	alternative,	thrombolysis	was	sometimes	associated	to	supposedly	facilitate	it.	Unexpectedly,	however,	the	benefit	of	facilitated	angioplasty	turned	out	to	be	reduced	in	comparison	with	the	non-
facilitated	intervention.	Degradation	of	circulating	HDL	may	provide	a	potential	mechanism	for	this	outcome.
Bikunin	is	a	25		kDa	proteinase	inhibitor	present	in	human	plasma	covalently	linked,	through	a	glycosaminoglycan	chain,	to	one	or	two	homologous	heavy	chains,	forming	high	molecular	weight	proteinase	inhibitors	called	pre-
alpha-	and	inter-alpha-inhibitor.	During	inflammation,	bikunin	synthesis	is	down-regulated,	still	its	excretion	in	urine	increases.	This	apparent	inconsistency	is	connected	with	neutrophil	activation	and	the	cleavage	of	the	inhibitor	from
the	C-terminus	of	the	heavy	chains	by	the	released	proteases	[108].
C-reactive	protein	or	CRP,	the	main	positive	acute	phase	reactant	protein	in	humans,	displays	several	functions	associated	with	host	defense:	it	promotes	agglutination,	bacterial	capsular	swelling,	phagocytosis	and	complement
fixation	through	its	calcium-dependent	binding	to	phosphorylcholine;	it	can	scavenge	nuclear	material	released	from	damaged	circulating	cells	interacting	with	DNA	and	histones.	CRP	is	part	of	a	complex	homeostatic	mechanism	that
governs	the	acute	phase	reaction,	regulating	the	immune	response	and	the	activity	of	matrix-degrading	enzymes.	It	is	noteworthy	that	different	properties	are	displayed	by	the	whole	pentameric	assembly	as	well	as	by	some	proteolytic
fragments.	For	instance,	while	native	CRP	does	not	induce	phagocytic	leukocytes	to	chemotax	or	to	produce	superoxide,	treatment	of	purified	CRP	with	human	neutrophil-derived	acid	proteases	produces	substances	with	potent	effects
on	leukocyte	function.	As	a	likely	explanation,	the	sequence	of	CRP	contains	peptides	closely	resembling	the	immunomodulator	tuftsin	[109].	In	contrast	to	the	inability	of	intact	CRP	to	inhibit	either	human	leukocyte	elastase	or	human
leukocyte	cathepsin	G,	both	associated	with	chronic	inflammatory	tissue	damage,	the	peptide	62‐–76	from	the	inner	disulfide	loop	of	human	CRP	inhibits	these	enzymes	at	concentrations	far	lower	than	the	acute-phase	concentration	of
the	 protein	 [110].	 CRP	 peptide	 201‐–206	 induces	L-selectin	 shedding	 from	 human	 neutrophils	 and	 inhibits	 L-selectin-mediated	 neutrophil	 adhesion	 to	 TNFalpha-activated	 human	 coronary	 artery	 endothelial	 cells	 under	 non-static
conditions.	It	also	attenuates	shear-induced	up-regulation	of	platelet	P-selectin	expression,	platelet	capture	of	neutrophils,	and	subsequent	homotypic	neutrophil	adhesion	in	human	whole	blood	[111].
4.1.2.4.1.2	Polymerization
This	section	is	much	shorter	than	the	previous	one	but	it	starts	with	albumin	as	well.	Circulating	homo-	and	hetero-polymeric	complexes	of	albumin	show	Mr	around	210,	168,	147,	132,	and	110		kDa	and	represent	between	0.3
and	2.8%	of	total	albumin	[112].	In	urine,	their	presence	is	an	obvious	marker	of	impairment	in	ultrafiltration	selectivity,	for	instance	in	association	with	lupus	glomerulonephritis	[113].	The	surface	antigen	of	hepatitis	B	virus	(HBsAg)
acts	as	a	receptor	for	polymerized	human	serum	albumin;	its	levels	are	predictive	of	the	outcome	of	the	disease	[114,115].
We	have	mentioned	above	the	main	steps	of	the	inhibition	operated	by	alpha-1-antitrypsin	on	elastase.	Pathological	mutations,	including	Glu342Lys	(Z),	subvert	its	peculiar	conformation	to	generate	a	polymerogenic	state	for
which	at	least	three	models	have	been	proposed.	The	classical	or	‘loop-sheet’	model	involves	an	intermolecular	linkage	via	the	reactive	loop	as	a	single	strand,	whereas,	in	the	beta-hairpin	model,	the	intermolecular	linkage	consists	of
two	beta-strands	and,	 in	the	triple-strand	model,	of	 the	three	C-terminal	beta-strands	of	alpha-1-antitrypsin	 [99,116,117].	Polymerization	occurs	mainly	at	 the	 time	of	alpha-1-antitrypsin	synthesis,	with	 the	 formation	of	PAS-positive
inclusions	inside	the	hepatocytes;	the	resulting	pathologically	low	concentration	of	the	circulating	protein	(below	the	protective	threshold	at	ca.	600		mg/L)	is	unable	to	prevent	proteolytic	damage	at	the	sites	of	inflammation	in	lungs.
However,	polymers	are	also	found	in	the	circulation	of	ZZ	subjects,	both	with	and	without	chronic	obstructive	pulmonary	disease	(median	concentration	around	40		mg/L	[118]).	Polymers	may	be	specifically	detected	with	a	monoclonal
antibody	that	recognizes	a	conformation-dependent	neoepitope	on	both	polymerized	and	elastase-complexed	molecular	forms	of	alpha-1-antitrypsin	[119].
4.1.3.4.1.3	Differential	glycosylation
In	recent	years	mass	spectrometry,	 in	combination	with	liquid	chromatography	or	capillary	electrophoresis,	can	reliably	assess	protein	glycosylation,	through	the	analysis	of	either	glycopeptides	(after	proteolysis)	or	glycans
(after	PNGase	F	or	chemical	treatment).	The	evidence	provided	by	these	approaches	is	sharpening	our	understanding	of	glycobiology:	as	exemplified	by	transferrin	[120,121],	a	protein	glycosylation	pattern	may	vary	depending	on	the
tissue	in	which	it	is	synthesized	or	the	biological	fluid	in	which	it	is	accumulated,	and	is	extensively	affected	by	different	physiological	and	pathological	states.
Much	effort	 for	 in-depth	 investigation	of	 these	phenomena	 is	 concentrated	on	pathological	 tissues.	A	number	of	 syndromes	are	being	studied	 in	 this	 respect,	 including	multiple	 sclerosis	 [122],	Alzheimer	disease	 [123]	 and
atherosclerosis	 [124].	 Main	 focus,	 however,	 is	 on	 cancer,	 as	 glycans	 are	 involved	 in	 such	 crucial	 aspects	 of	 the	 disease	 as	 cell	 signaling	 and	 communication,	 tumor	 cell	 dissociation	 and	 invasion,	 cell-matrix	 interactions,	 tumor
angiogenesis,	immune	modulation	and	metastasis	formation	[125–129].
Most	proteins	 in	plasma/serum	are	glycoproteins;	 for	 each	of	 them	a	number	of	microheterogeneous	 species	 (glycoforms)	may	be	 recognized.	Systematic	 changes	 in	glycosylation	of	plasma/serum	proteins	are	observed	 in
connection	with	cancer,	as	exemplified	by	ovarian	carcinoma	[130].	Cancer	cells	produce	inflammatory	cytokines	that	influence	glycosylation	in	hepatocytes	with	an	increase	in	sialyl	LewisX.	Sialylation	of	acute	phase	proteins	increases
their	half-life	and	confers	anti-apoptotic	properties	thus	favoring	the	survival	of	cancer	cells.	Data	on	glycosylation,	e.g.	 the	compound	influence	of	branching	and	fucosylation,	may	be	taken	as	marker	of	carcinoma	progression	and
prognosis	[131].	A	report	on	experimental	mouse	cancers	detected	an	increase	in	internal	Neu5Gcalpha2‐–6	sialylation	on	the	GlcNAc	of	the	Neu5Gc2-3Gal1-3GlcNAc	terminal	sequence	as	a	common	feature	but	found	the	substitution	of
Neu5Gc	by	Neu5Ac	to	be	induced	by	colon	and	not	by	breast	tumor.	Among	the	abundant	serum	components,	transferrin	was	found	to	change	significantly	in	terminal	glycosylation	pattern	but	not	in	overall	expression	level	[132].
Glycosylation	of	plasma/serum	proteins	is	also	affected	in	all	types	of	diseases	featuring	an	inflammatory	component	[133].	alpha-1-acid	glycoprotein	(AGP)	is	the	most	extensively	glycosylated	of	plasma/serum	proteins	(over
50%	 by	weight)	 and	 is	 a	 positive	 acute	 phase	 reactant,	 its	 concentration	 increasing	 between	 5-	 and	 50-fold	 in	 response	 to	 noxa.	Within	 the	 calycin	 superfamily,	 lipocalin	 family,	 it	 belongs	 to	 the	 subfamily	 of	 immunocalins.	 The
immunomodulatory	 and	binding	properties	 of	 alpha-1-acid	 glycoprotein	 strongly	 depend	on	 its	 carbohydrate	 composition:	 strikingly,	 different	 glycoforms	bring	 about	 opposite	 immunomodulatory	 effects	whereas	 a	 pool	 of	N-linked
oligosaccharide	chains	attached	to	a	soluble	polyacrylamide	matrix	display	a	similar	activity	 to	 its	parent	AGP	 in	 the	biological	 tests	 [134].	The	protein	glycosylation	pattern	 is	modified	by	disease:	 in	acute	 inflammation,	a	relative
increase	of	AGP	glycoforms	with	biantennary	units	is	observed	(a	type	I	glycosylation	change).	Conversely,	in	some	chronic	inflammatory	states	there	is	a	relative	decrease	of	AGP	glycoforms	with	biantennary	heteroglycans	(a	type	II
glycosylation	change).	This	same	type	of	glycosylation	changes	is	also	seen	in	pregnancy,	during	estrogen	administration	or	upon	liver	damage	[135].	For	all	these	reasons,	AGP	is	regarded	as	a	model	and	extensively	investigated	[136].
alpha-1-antitrypsin	both	inhibits	serine	proteases	and	is	involved	in	immunomodulation	through	effects	on	neutrophil	chemotaxis,	immune	complex	signaling	and	apoptosis;	it	appears	that	the	glycans	of	alpha-1-antitrypsin	are
more	important	for	the	latter	functions	rather	than	for	the	former	[137].
A	completely	different	area	of	glycobiology	to	which	the	analysis	of	plasma/serum	glycoproteins	is	relevant	is	the	laboratory	diagnosis	of	congenital	disorders	of	glycosylation.	For	disorders	of	N-glycosylation,	causal	mutations
occur	in	at	least	12	different	genes,	which	encode	monosaccharide	transferases	of	the	endoplasmic	reticulum.	Transferrin	is	often	taken	as	the	reference	material	for	the	analysis	of	glycosylation	anomalies:	by	mass	resolution,	the	under-
glycosylation	of	transferrin	is	characterized	as	the	total	absence	of	one	or	both	N-linked	oligosaccharides	[138].
Despite	great	advancements,	the	current	procedures	for	direct	glycan	assessment	outlined	in	the	first	 lines	of	this	section	are	still	complex	and	lengthy.	However,	due	to	the	influence	of	glycosylation	on	both	pI	and	Mr	of	a
protein,	the	quantitation	of	all	the	species	with	2DE	experiments,	under	conditions	allowing	their	resolution,	is	a	straightforward	and	efficient	approach	to	differentiate	various	physiological	and	pathological	conditions.
4.2.4.2	Inflammation	markers
Inflammation	is	such	a	broad	and	general	phenomenon	that	its	occurrence	cannot	be	taken	as	diagnostic	of	any	specific	condition.	However,	its	detailed	course	is	finely	tuned	by	the	interplay	of	several	factors	and	some	features
vary	from	one	case	to	another.
The	secretion	of	plasma/serum	proteins	by	the	liver	follows	two	main	patterns.	Proteins	such	as	CRP,	serum	amyloid	A	and	alpha-1-acid	glycoprotein,	which	require	the	synergistic	action	of	IL6	and	IL1	for	maximal	induction,	are
said	type	1	acute	phase	reactants	(APRs).	Proteins	such	as	fibrinogen,	haptoglobin,	and	alpha-2-macroglobulin,	which	only	depend	on	IL6	for	up-regulation,	are	said	type	2	APR;	often	their	synthesis	is	suppressed	rather	than	enhanced
by	IL1.	Some	cytokines	are	selective	in	inducing	one	or	few	APRs;	cytokines	and	other	mediators	interact	in	additive,	synergistic,	co-operative,	and	antagonistic	ways.	For	instance,	as	seen	in	cultured	hepatoma	cells	(HepG2),	four	of
them	–	—	IL1,	IL6,	TNF-alpha	and	TGF-beta	–	—	are	required	to	coordinately	induce	the	synthesis	of	alpha-1-antichymotrypsin	while	repressing	that	of	albumin	and	alpha-fetoprotein.	As	a	result	of	the	above,	individual	inflammatory
proteins	differ	in	time-course	(rapid-	vs	slow-reacting	APRs)	as	well	as	in	direction	and	extent	of	change	in	their	circulating	concentration	(major	positive	vs	moderate	positive	vs	negative	APRs).
The	acute	phase	proteins	function	as	mediators	and	inhibitors	of	inflammation,	regulate	immune	responses,	act	as	transport	proteins	for	products	generated	during	the	inflammatory	process,	and/or	play	an	active	role	in	tissue
repair	and	tissue	remodeling.	At	 least	some	acute	phase	proteins	might	constitute	an	 inducible	system	of	 factors	protecting	against	cell	death	by	apoptosis:	 for	 instance,	alpha-1-acid	glycoprotein	and	alpha-1-antitrypsin	 inhibit	 the
activation	of	caspase-3	and	caspase-7	to	become	the	main	effectors	(executioners)	of	apoptosis	[139].
Some	APRs	behave	 like	cytokines:	CRP	activates	macrophages,	migration	 inhibition	 factor	 (MIF)	prevents	chemotaxis.	The	APRs	with	anti-proteolytic	activity	block	 the	migration	of	cells	 into	 the	 lumen	of	blood	vessels	and
prevent	the	establishment	of	a	generalized	systemic	inflammation.
The	above	summary	(taken	from	the	Cytokines	&	cells	online	pathfinder	encyclopedia	(COPE)	website	at	www.copewithcytokines.org)	reminds	the	complexity	of	the	issue.	Because	they	vary	during	the	course	of	an	inflammatory
condition,	group	analysis	of	APRs	(serum	APR	profile)	is	no	doubt	more	meaningful	than	measuring	any	single	protein	[140];	APR	profiles	should	involve	at	least	one	major	(CRP	or	serum	amyloid	A,	SAA),	one	moderate	(haptoglobin,
alpha-1-acid-glycoprotein,	or	ceruloplasmin),	and	one	negative	APR.	Calculation	of	an	index	from	values	of	rapid-	and	slow-reacting	positive	and	negative	APRs	has	been	repeatedly	proposed	in	veterinary	medicine,	because	it	appears	to
increase	statistical	sensitivity	and	specificity	for	detecting	non-healthy	subjects	[141].
Examples	of	disease-specific	 associations	 for	 some	APRs	are	provided	by	 two	 reports.	 Inoculation	 into	nude	mice	of	human	cancer	 cell	 lines	derived	 from	stomach,	nasopharyngeal,	 colon,	 oral	 and	brain	 cancers	 results	 in
increased	levels	of	several	mouse	APRs,	including	haptoglobin.	Conversely,	serum	amyloid	A	(SAA),	is	found	only	in	mice	bearing	tumors	induced	by	the	stomach	cancer	cell	line	(SC-M1)	[142].	In	a	genetically	modified	mouse	model
(gp130F/F)	 that	 develops	 a	 gastric	 adenoma	 phenotype,	 the	most	 acidic	 isoforms	 of	 alpha-1-antitrypsin	 are	 down-regulated	 and	 the	most	 alkaline	 are	 up-regulated	 in	 tumourtumor-bearing	 relative	 to	 the	 tumourtumor-free	 cohorts
[143,144]	–	—	this	latter	case	(Fig.	9)	being	connected	as	well	to	the	issue	of	differential	glycosylation	in	Section	4.1.3.
The	highlighted	intricacy	of	cross-influences	should	suggest	the	relevance	of	a	detailed	investigation	of	the	actual	pattern	of	APRs:	in	individual	clinical	cases	it	could	sharpen	the	diagnostic	power	of	multifactorial	information,	in
individual	animal	models	of	disease	it	could	help	understanding	the	mechanisms	of	disease.	A	significant	factor	for	the	latter	is	the	number	and	variety	of	activities	each	of	the	APR	may	be	involved	in,	as	sketched	in	the	above	and
specified	in	the	following.
4.3.4.3	Moonlighting	proteins?
Fig.	9	DIGE	of	serum	from	a	gastric	cancer	mouse	model,	highlighting	differentially	regulated	alpha-1-antitrypsin	isoforms;	box-and-whisker	plots	representing	the	average	spot	volume	associated	with	alpha-1-antitrypsin	in	mouse	serum,	showing	up-
regulation	(top	panel,	acid	spots)	and	down-regulation	(bottom	panel,	basic	spots)	in	tumourtumor-bearing	relative	to	the	tumourtumor-free	cohort.	(From	[144]).
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The	growing	evidence	that	a	single	polypeptide	chain	–	—	a	single	protein	or,	better,	a	single	protein	species	or,	when	relevant,	a	single	protein	domain	–	—	can	sometimes	perform	multiple	physiologically	relevant	biochemical	or
biophysical	functions	is	attracting	attention	on	moonlighting	(multifunctional	or	multitasking)	proteins	[145].	The	ability	to	moonlight	is	one	of	the	ways	used	by	cells	to	carry	out	many	complex	processes	with	a	limited	number	of	genes.
Ancestral	moonlighting	proteins	originally	performed	a	single	function,	usually	enzymatic	catalysis,	but,	through	evolution,	they	have	then	acquired	secondary	non-enzymatic	roles	e.g.	as	receptors,	ion	channels	or	chaperones.	Some
moonlighting	proteins	can	perform	both	functions	simultaneously	but	others	switch	roles	depending	on	various	factors	including	the	cell	type	in	which	they	are	expressed,	their	cellular	location,	the	oligomerization	status	and	the	binding
of	 different	 ligands	 at	 different	 sites.	 Databases	 collecting	 and	 organizing	 information	 about	 the	 few	 hundreds	 of	 characterized	 moonlighting	 proteins	 are	 MultitaskProtDB	 at	 http://wallace.uab.es/multitask	 [146]	 and	 MoonProt
http://www.moonlightingproteins.org	[147].	First	attempts	have	started	towards	the	computational	characterization	of	moonlighting	proteins	[148]	and	their	identification	via	bioinformatics	tools	[149].
No	plasma/serum	protein	is	listed	in	the	above	databases,	which	only	include	cellular	protein	components.	Antibodies	have	been	discussed	in	this	perspective	to	conclude	that,	while	they	do	moonlight	as	a	class	(as	they	bind	to
multiple	 antigen	 ligands),	 they	 do	 not	 as	 individual	 proteins	 (since	 the	 multiple	 functions	 they	 perform	 are	 encoded	 in	 different	 domains)	 [150].	 Ceruloplasmin,	 on	 the	 contrary,	 in	 a	 review	 article	 has	 been	 acknowledged	 as	 a
moonlighting	protein	[151].	This	plasma/serum	glycoprotein	is	involved	in	copper	transport	and	storage	by	binding	6‐–7	atoms	of	metal	per	molecule.	There	is	a	question,	though,	on	how	the	various	enzymatic	activities	the	protein	is	able
to	perform	(as	ferroxidase,	ascorbate	oxidase,	nitric	oxide	oxidase)	are	shared	between	the	various	metal	binding	sites.	These	activities	may	eventually	result	in	a	variety	of	effects:	degradation	of	organic	substrates	and	defense	against
oxidant	stress	and	overall	anti-oxidant (split	word:	oxi-dant	(see	pdf))	activity	or,	conversely,	under	peculiar	circumstances,	pro-oxidant	activity.
Without	ever	being	mentioned	as	such,	some	plasma/serum	proteins	actually	conform	to	the	definition	of	moonlighters.	For	instance,	it	has	long	been	known	that	sharply	distinct	parts	of	the	molecule	of	alpha-1-acid	glycoprotein
are	relevant	either	in	ligand	binding	(the	inner	cavity,	or	calyx)	or	immunomodulation	(the	glycidic	chains,	see	in	Section	4.1.3).	Other	proteins	are	still	becoming	associated	with	previously	unrecognized	functions.	Due	to	its	scattered
nature,	relevant	literature	is	not	easily	searched	for	by	keywords;	the	two	examples	in	the	following	paragraphs	should	be	taken	as	anecdotal	rather	than	exhaustive	on	recent	advances.
Acute-phase	serum	amyloid	A	isoforms	(SAA1,	SAA2,	and	SAA3)	are	secreted	during	the	acute	phase	of	inflammation.	They	are	known	to	have	several	roles,	including	the	transport	of	cholesterol	to	the	liver	for	secretion	into	the
bile,	the	recruitment	of	immune	cells	to	inflammatory	sites,	and	the	induction	of	enzymes	that	degrade	extracellular	matrix.	It	has	recently	been	demonstrated	that	human	(and	mouse)	SAAs	also	bind	retinol	with	nanomolar	affinity;	the
crystal	structure	of	the	complex	is	that	of	a	tetramer	with	a	hydrophobic	pocket.	During	infection,	SAAs	are	up-regulated	and	their	binding	retinol	in	vivo	contributes	to	limit	the	bacterial	burden	in	tissues	[152].	Hematopoietic	tissue
retains	pools	of	stem	cells	and	provides	a	microenvironment	for	progenitor	cell	renewal	throughout	life.	In	adults,	hematopoiesis	is	dependent	on	the	chemokine	receptor	CXCR4	and	its	ligand	CXCL12.	An	additional	role	is	played	by
elastase	that,	when	bound	to	leukocyte	surface,	acts	as	a	receptor	for	alpha-1-antitrypsin.	Binding	of	antiprotease	to	protease	forms	a	motogenic	complex	[153].	In	the	blood	of	HIV-1	patients,	alpha-1-antitrypsin (split	word:	anti-trypsin	for
line-break	(see	pdf))	is	bound	and	inactivated	by	anti-HIV-1	gp120	antibodies;	the	presence	of	such	immune	complexes	correlates	with	the	decrease	in	number	of	CD4+	lymphocytes	in	these	subjects	[154].
In	a	more	general	perspective,	chaperone-assisted	protein	folding	is	one	of	the	processes	that	concur	to	proteostasis,	i.e.	the	maintenance	of	adequate	levels	of	individual	proteins	in	their	correct	folding	state	(Fig.	10).	We	have
mentioned	 that	 intracellular	 chaperoning	 is	 one	 of	 the	 additional	 functions	moonlighting	 proteins	 are	 often	 performing.	Recent	 research	 has	 recognized	 among	 plasma/serum	proteins	 a	 growing	 number	 of	 abundant	 extracellular
chaperones	constitutively	secreted	in	body	fluids,	which	act	as	both	sensors	and	disposal	mediators	for	misfolded	proteins	[155].	The	chaperones	selectively	bind	to	exposed	hydrophobic	regions	on	misfolded	proteins	to	prevent	them
from	aggregating	in	the	form	of	toxic	insoluble	deposits	(such	as	those	seen	in	type	II	diabetes	and	Alzheimer’'s	and	prion	disease).	The	same	chaperones	are	also	implicated	in	clearing	from	body	fluids	the	soluble,	stabilized	misfolded
proteins	via	receptor-mediated	endocytosis	for	subsequent	lysosomal	degradation	[156].
Clusterin,	 haptoglobin	 and	 alpha-2-macroglobulin	 are	 the	 plasma/serum	 components	most	 directly	 associated	 with	 extracellular	 chaperone	 function	 but	 individual	 reports	 have	 investigated	 such	 property	 for	 a	 number	 of
abundant	proteins	(apo	E	isoforms	different	from	the	ε4	allele,	fibrinogen,	alpha-1-acid	glycoprotein	and	lipocalin-type	prostaglandin	D	synthase).	Albumin	is	considerably	less	efficient	at	preventing	protein	aggregation	than	recognized
chaperones	but,	given	its	abundance,	its	activity	may	be	physiologically	relevant	(e.g.	to	prevent	amyloid	formation	by	Abeta	and	by	the	Val30Met	mutant	of	transthyretin).
4.4.4.4	Cross-regulation
Extremely	reduced	levels	of	individual	proteins	or	their	complete	absence	from	the	circulation	as	a	result	of	mutations	in	the	genes	coding	for	some	major	plasma/serum	components	are	observed	as	rare	recessive	disorders.	The
pathological	consequences	each	of	the	conditions	entails	vary	in	penetrance	and	severity.	Nature	and	range	of	the	effects	help	define	the	function	of	the	individual	protein	as	well	as	the	redundancy	of	effectors	that	may	vicariate	for	the
missing	component.	Moreover,	changes	 in	 the	 levels	of	other	components	of	plasma/serum	proteome	assess	mode	and	strength	of	 the	cross-regulation	among	protein	concentrations.	 In	addition	to	 the	analysis	of	 the	spontaneously
occurring	null	phenotypes	in	the	human	population,	these	aspects	of	proteostasis	might	be	studied	in	such	animal	models	as	the	knock-out	(KO)	mice.
In	 line	with	the	marginal	 interest	plasma/serum	proteins	are	currently	receiving,	however,	we	could	find	in	the	literature	a	satisfactory	description	of	 just	one	genetic	disease,	analbuminemia,	and	of	 just	one	genetic	model,
knocking-out	of	apolipoprotein	A-I;	only	the	latter	was	studied	comprehensively	with	up-to-date	proteomics	tools.	No	comparable	data	have	been	published	e.g.	regarding	the	disease	that	involves	the	second	most	abundant	plasma/serum
protein	‐	—	atransferrinemia,	characterized	by	abnormal	synthesis	of	transferrin	and	leading	to	iron	overload	and	microcytic	hypochromic	anemia.	Nor	are	reports	available	regarding	alpha-1-antitrypsin	deficiency,	connected	with	the	Z
(Glu342Lys)	or	the	S	mutants	(Glu288Val),	inherited	in	the	ZZ	and	SZ	genotypes,	much	more	often	than	with	a	null‐–null	setup.	The	most	common	manifestation	of	the	disorder	is	emphysema,	which	becomes	evident	by	the	third	to	fourth
decade;	a	less	common	manifestation	is	liver	disease,	which	occurs	in	children	and	adults,	and	may	result	in	cirrhosis	and	liver	failure.	In	some	populations,	the	frequency	of	the	Z	or	S	genes	is	especially	high,	which	has	been	tentatively
connected	with	heterozygote	advantage	against	lung	infections.
Analbuminemic	 individuals	manifest	mild	 edema,	 hypotension	 and	 fatigue.	 The	most	 common	 biochemical	 finding	 is	 hyperlipidemia,	with	 a	 significant	 increase	 in	 the	 total	 and	 LDL	 cholesterol	 concentrations,	 but	 normal
concentrations	of	HDL	cholesterol	and	triglycerides.	In	vivo	studies	with	continuous	infusion	of	labeled	amino	acids	(stable	isotope)	in	analbuminemic	subjects	detected	increased	production	of	IDL,	LDL	and	VLDL	and	delayed	clearance
of	VLDL	(apoB).	Because	albumin	increases	lipoprotein	lipase	activity	by	binding	free	fatty	acids,	which	are	strong	inhibitors	of	this	enzyme,	hypoalbuminemia	could	be	a	key	factor	in	the	low	VLDL	clearance.	A	higher	ratio	of	cholesterol
to	TG	in	apoB-containing	particles	and	an	increase	in	the	proportion	of	cholesterol	ester	relative	to	protein	could	explain	the	defective	catabolism	[157].	The	findings	are	similar	across	species	e.g.	in	analbuminemic	rats	[158].	Overall,
total	plasma/serum	protein	level	is	maintained	within	reference	values	through	the	compensatory	increase	in	globulin	concentration.	Differential	regulation	is	observed;	the	liver	increases	at	the	same	time	synthesis	and	secretion	of	both
positive	 and	 negative	 APRs	 (of	 transferrin,	 hemopexin,	 ceruloplasmin	 and	 fibrinogen	 and	 to	 a	 lesser	 extent	 of	 alpha-1-antitrypsin,	 alpha-1-antich ymotrypsin,	 alpha-2-macroglobulin,	 not	 of	 alpha-1-acid	 glycoprotein)	 [159]
Immunocompetent	cells	also	increase	the	synthesis	of	immunoglobulins	(IgG,	IgA	and	IgM).	Hypercholesterolemia	in	analbuminemic	rats	is	associated	with	increased	level	but	unmodified	activity	of	hepatic	HMG‐
CoA	 reductase,	 which	 points	 to	 a	 post-translational	 regulation	 of	 this	 enzyme	 and	 favors	 an	 extrahepatic	 origin	 of	 hypercholesterolemia	 in	 these	 animals.	 Cholesterol	 7-alpha-hydroxylase	 is	 up-regulated	 as	 a	 compensatory
response	to	hypercholesterolemia	[160].
An	effect	on	lipid	metabolism	similar	to	that	in	analbuminemia	is	observed	in	patients	with	nephrotic	syndrome,	in	whom	the	concentration	of	circulating	albumin	is	lowered	by	increased	loss	instead	of	by	reduced	synthesis.	At	a
difference	 from	analbuminemia,	nephrotic	syndrome	causes	severe	deficiencies	 in	LDL	receptor,	HDL	receptor,	and	LCAT.	The	hepatic	response	 in	conditions	characterized	by	reduced	plasma	colloid	osmotic	pressure	 (hypo-oncotic
states)	involves	increased	levels	of	mRNAs	encoding	a	group	of	secreted	proteins,	including	the	negative	APPs	albumin,	transferrin	and	apo	A-I,	and	the	positive	APR	fibrinogen.	Levels	of	mRNAs	encoding	negative	APRs	and	fibrinogen
correlate	with	one	another,	suggesting	that	they	are	coordinately	controlled.	The	transcription	factors	EGRF-1	and	HNF-4	seem	to	be	involved	in	this	regulation	[161].
Animal	 models	 of	 primary	 hypertriglyceridemia	 (apoCIII	 transgenic	 mice)	 and	 hypercholesterolemia	 (LDL	 receptor	 knockout	 mice)	 show	 higher	 susceptibility	 to	 Ca2	 +-induced	 inner	 mitochondrial	 membrane	 permeability
transition	(MPT),	a	process	that	can	lead	to	cell	death	as	 it	 is	 followed	by	mitochondrial	energy	failure	and	the	release	of	pro-apoptotic	factors.	Both	men	and	mice	with	analbuminemia,	who	present	high	levels	of	triglycerides	and
Fig.	10	Major	elements	of	extracellular	proteostasis.	Proteins	undergo	rigorous	quality	control	before	they	are	secreted,	generally	in	a	natively	folded	state.	Once	in	the	extracellular	environment,	they	encounter	a	variety	of	stressors	that	can	cause	them	to
partially	unfold	and	populate	misfolded	states.	Misfolded	proteins	can	aggregate	into	soluble	oligomers	and	subsequently	into	insoluble	fibrillar	or	amorphous	aggregates.	Extracellular	chaperones	form	stable	complexes	with	misfolded	protein	species,
including	misfolded	monomers	and	oligomers.	These	complexes	maintain	misfolded	proteins	in	solution	and	facilitate	their	clearance	from	extracellular	fluids	via	receptor-mediated	endocytosis	and	subsequent	degradation	in	lysosomes.	In	some	cases,
misfolded,	modified,	or	aggregated	proteins	can	also	be	cleared	via	receptor-mediated	endocytosis	without	the	involvement	of	extracellular	chaperones;	large	insoluble	aggregates	must	be	phagocytosed.	Furthermore,	extracellular	proteases,	such	as	plasmin,
may	be	activated	by	protein	aggregates	and	subsequently	degrade	them.	(From	[155]).
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cholesterol,	also	present	abnormal	mitochondrial	functions.	The	search	for	putative	mediators	of	MPT	sensitization	in	mice	revealed	a	30%	increase	in	the	expression	of	the	apoptotic	regulator	cyclophilin	D	together	with	a	20%	decrease
in	mitochondrial	nitrosothiol	content:	nearly	80%	of	total	plasma	reduced	thiol	groups	and	nitrosothiols	reside	in	albumin	molecules	[162].
Our	investigation	on	animals	compared	mice,	in	which	murine	apoA-I	had	been	knocked	out,	to	derived	strains	made	transgenic	for	human	apoA-I,	human	apoA-II,	or	both	[163]	(Fig.	11).	The	absolute	abundance	of	human	apoA-I
was	not	influenced	by	the	presence	apoA-II,	conversely	the	presence	of	the	apoA-I	transgene	resulted	in	a	statistically	significant	increase	in	expression	of	the	apoA-II	transgene.	Several	proteins	not	involved	in	lipid	metabolism	were
also	influenced	by	the	presence	of	human	apolipoprotein	transgenes,	with	apoA-I	exerting	a	much	greater	effect	than	apoA-II.	All	the	proteins	whose	levels	are	modulated	by	the	expression	of	human	apolipoprotein	transgenes	‐	—	alpha-
1-acid	glycoprotein,	alpha-1-macroglobulin,	esterase,	haptoglobin	and	contrapsin	‐	—	have	cytokine-responsive	elements	in	their	promoter	region	and	are	known	to	be	involved	in	acute	phase	reactions.	The	inhibitory	effect	of	HDL	on
cytokine	secretion	[164–166]	could	be	the	explanation	for	our	observations	on	the	effect	of	expression	of	apolipoprotein	transgenes.
4.5.4.5	Immunoglobulins
Immunoglobulins	form	a	large	and	heterogeneous	class	of	plasma/serum	proteins;	because	of	their	origin	from	differentiated	B	cells	of	the	adaptive	immune	system	(instead	of	liver)	and	because	of	their	role	as	antibodies	they
deserve	a	comment	on	their	own	in	addition	to	unsystematic	mention	in	previous	sections	of	this	review.
Gamma,	kappa	and	lambda-type	chains	have	more	alkaline	pIs	than	most	other	major	plasma/serum	proteins;	their	removal	is	relevant	for	reducing	overall	protein	load	more	than	for	preventing	spot	comigration.	The	affinity	of
many	Ig	classes	for	protein	A	or	G	has	been	repeatedly	exploited	for	their	subtraction;	some	commercial	products	feature	mixes	of	resin-immobilized	protein	A	or	G	with	a	resin-immobilized	tr iazine	dye	(e.g.	from	BioRad)	or	a	resin-
immobilized	anti-albumin	antibody	 (e.g.	 from	Biosystems	or	Sartorius)	 for	 the	removal	of	 the	 two	most	abundant	proteins/protein	classes	 in	plasma/serum	namely	albumin	and	 Igs.	 Immunoglobulin 	precipitation	at	50%	ammonium
sulfate	saturation	is	a	classical	procedure	in	the	production	of	reagent	antibodies,	at	both	laboratory	and	industry	scale	[167].
Proteomic	procedures	have	been	systematically	applied	to	the	field	of	immunology	in	order	to	recognize	‐	—	in	bacteria	(e.g.	Neisseria	meningitidis	[168]	or	Chlamydia	trachomatis	[169]),	fungi	(e.g.	Aspergillus	fumigatus	[170]),
(pluricellular)	parasites	(e.g.	Amblyomma	americanum	[171]),	or	cancer	cells	(e.g.	prostate	cancer	[172])	–	—	against	which	non-self	proteins	the	host	organism	raises	the	most	intense	reaction.	This	is	achieved	by	separating	by	2DE	the
proteome	of	the	pathogens	or	some	relevant	subproteome	e.g.	membrane	proteins,	and	by	using	serum	from	affected	patients	as	a	source	of	primary	antibodies	in	immunoblotting.	Proteins	in	repeatedly	detected	spots	are	identified
through	MS	procedures;	acknowledged	immunodominant	antigens	are	taken	as	targets	of	preventive	and/or	therapeutic	vaccines.	This	way	of	proceeding	has	been	given	the	name	of	immunoproteomics	and	focuses	on	the	complement	of
all	identified	antigens	in	a	pathogen	[173].	Alternative	experimental	approaches	to	electrophoresis	imply	the	use	of	protein	arrays	of	the	pathogen.
The	same	approach	is	able	to	recognizes	transversal	and	longitudinal	variations	in	the	immunoproteome.	The	latter	of	course	most	easily	apply	to	situations	in	which	a	pathogen	exists	in	different	forms	with	time	such	as	the
alteration	of	immunoproteome	profile	of	Echinococcus	granulosus	hydatid	fluid	with	progression	of	cystic	echinococcosis	[174].	The	former	allow	for	the	discrimination	of	more	and	less	severe	outcome	of	a	given	condition.	For	instance,
Fig.	11	Variation	in	protein	expression	in	mice	transgenic	for	human	apolipoprotein	A-I	(apoAI),	for	human	apolipoprotein	A-II	(apoAII)	and	for	both	(apoAI/II),	and	in	their	genetic	background	(mice	KO	for	murine	apolipoprotein	A-I,	KO).	(From	[163]).
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the	evolution	of	the	infection	and	the	replicative	state	of	the	pathogen	appear	to	affect	the	immunoproteome	of	Mycobacterium	tuberculosis,	shifting	target	from	membrane-associated	to	extracellular	proteins	of	the	bacillus	during	the
active	phase	of	the	disease.	Overall,	the	immune	response	correlates	with	bacillary	burden	but	target	preferences	vary	among	patients;	diagnosis	and	monitoring	treatment	outcome	may	benefit	fro m	the	use	of	the	identified	biomarkers
[175].	Finally,	Helicobacter	pylori	infection	may	progress	into	ulcer	or	into	cancer,	a	predisposing	condition	to	the	latter	being	atrophic	body	gastritis.	Different	investigations	have	been	able	to	associate	Helicobacter	immunoproteome
with	the	different	conditions.	Three	proteins	have	been	identified	as	duodenal	ulcer-related	[176];	sera	from	atrophic	body	gastritis	and	gastric	cancer	patients	differentially	recognize	17	Helicobacter	spots	[177].
Through	differences	in	the	immune	targeting	the	investigations	above	exemplify	on	the	interaction	between	self	and	non-self	during	infection/infestation.	Tissot	and	colleagues	have	evaluated	the	application	of	typical	proteomic
procedures	such	as	2DE	to	the	diagnostics	of	lymphoid	tissue	cancers.	A	classification	of	the	monoclonal	IgGs	of	multiple	myelomas	based	only	on	their	electrophoretic	properties	turned	out	not	to	be	possible	because	of	the	extreme
diversity	among	the	pathological	heavy	and	light	chains	[178].	To	this	purpose,	the	overall	performance	of	high-resolution	electrophoresis	was	lower	than	that	of	zonal	electrophoresis	with	immunofixation.	However	the	opposite	is	true	in
selected	cases,	for	instance	with	the	characterization	of	rare	IgD	myeloma	[179]	or	with	the	classification	of	cryoglobulins	[180].
The	role	of	immunoglobulin	glycosylation	has	long	been	studied	[181,182].	As	reviewed	in	[183],	current	investigation	areas	include:	the	glycosylation	sites	of	IgE,	IgM,	IgD,	IgE,	IgA,	and	IgG;	how	glycans	can	encode	"“self"
identity	by	functioning	as	either	danger	associated	molecular	patterns	or	self-associated	molecular	patterns	(SAMPs);	the	role	of	glycans	as	markers	of	protein	integrity	and	age;	how	the	glycocalyx	can	dictate	the	migration	pattern	of
immune	cells;	and	how	the	combination	of	Fc	N-glycans	and	Ig	isotype	dictate	the	effector	function	of	immunoglobulins.	Recently,	it	has	been	demonstrated	that	a	single	glycan	on	IgE	is	indispensable	for	initiation	of	anaphylaxis	[184]
In	 immunoglobulin	 A	 nephropathy,	 galactose-deficient	 immunoglobulin	 A (non-Italics)1	 is	 recognized	 by	 unique	 autoantibodies,	 resulting	 in	 the	 formation	 of	 pathogenic	 immune	 complexes	 that	 ultimately	 deposit	 in	 the	 glomerular
mesangium	and	induce	renal	injury.	New	approaches	using	MS	have	provided	insight	at	pathological	IgA1	glycosylation	as	connected	with	abnormal	expression	and	activity	of	several	key	glycosyltransferase	[185].
5.5	Conclusions
Knowledge	 of	 the	 properties	 of	 proteins	 and	understanding	 of	 their	working	 is	 steadily	 growing;	 both	 shared	 features	 and	 individual	 traits	 come	 anew	on	 focus.	 The	 interest	 is	 currently	more	 on	 cellular
components	than	on	plasma/serum	proteome,	yet	recent	advancements	–	—	dutifully	recorded	in	this	review	–	—	have	been	achieved	also	on	circulating	proteins.	We	maintain	that	not	overlooking	information	provided
by	quali-	and	quantitative	changes	in	major	serum/plasma	proteins	may	effectively	contribute	to	our	awareness	of	the	cross-influences	between	various	levels	of	integration	in	the	organism.
Supplementary	data	to	this	article	can	be	found	online	at	http://dx.doi.org/10.1016/j.jprot.2016.04.002.
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An	 opposite	 perspective	 to	 depletion	 of	 high-abundance	 proteins	 from	 plasma/serum	 is	 the	 enrichment	 of	 low-abundance	 ones	 through	 an	 increase	 of	 their	 relative	 concentration;	 such	 a
compression	 of	 the	 dynamic	 range	 is	 expected	 to	 provide	 a	 deeper	 proteome	 profiling.	 This	 technology	 was	 described	 by	 the	 inventors	 as	 “protein	 equalization”	 and	 its	 effect	 as	 approaching	 a
"“democratic	proteome"”	 [33].	 The	 enrichment	 procedure	 is	 based	 on	 a	 specific	 and	 saturable	 interaction	 of	 proteins	 to	 a	 high	 diversity	 of	 binding	 sites	 exposed	 on	 chromatographic	 beads.	 The
combinatorial	ligand	library	is	made	up	of	dozens	of	millions	of	hexapeptides	capable	of	interacting	with	most,	if	not	all,	proteins	in	any	given	proteome	[34,35]	(Supplementary	Figs.	1	and	2).	BioRad
(http://www.bio-rad.com/)	markets	the	corresponding	commercial	kit,	ProteoMiner,	together	with	4	elution	reagents	meant	to	sequentially	recover	proteins	on	the	basis	of	different	properties,	in	a	format
compatible	with	analysis	by	SELDI.	Differential	elution	under	native	conditions	may	be	achieved	by	changing	the	pH	of	the	buffer	[36]	or	by	using	a	mixture	of	charged	aminoacids	(150		mM	Lys,	Arg,
Asp	and	Glu)	[37].	Elution	of	all	bound	proteins	under	denaturing	conditions	is	made	possible	by	boiling	the	beads	in	SDS	[38,39];	precipitation	with	acetonitrile	then	provides	for	the	highest	protein
recovery	yield	and	the	best	2DE	spot	pattern	[40].
The	conceptual	background	to	the	peptide	ligand	library	capture	is	a	saturation	effect:	all	the	proteins	present	in	the	starting	sample	in	concentrations	high	enough	to	overload	their	interaction
sites	on	the	beads	should	be	bound	in	equal	amounts,	the	excess	being	discarded	with	the	flow-through.	After	stripping	the	bound	proteins	from	the	resin,	the	concentration	of	the	higher-abundance
proteins	 should	 be	 equalized	 in	 the	 eluted	 fraction.	 Conversely,	 the	 proteins	 present	 in	 the	 starting	 sample	 in	 concentrations	 too	 low	 to	 overload	 their	 interaction	 sites	 on	 the	 beads	 should	 be
quantitatively	bound.	Accordingly,	the	differences	among	samples	should	be	intentionally	abolished	(or	at	least	reduced)	for	higher-abundance	and	preserved	for	lower-abundance	proteins.	A	test	of	the
quantitative	performance	of	the	capture	beads	shows	an	average	variability	around	10%	in	the	amount	of	the	isolated	proteins,	independent	of	their	initial	abundance.	No	normalization	effect	is	in	fact
observed	but,	depending	on	the	protein-to-bead	ratio,	specific	sets	of	proteins	are	either	enriched	or	depleted	vs	the	starting	whole	proteome	[43]	(Supplementary	Fig.	3).	All	reports	that	evaluate	the
performance	of	the	protein	enrichment	strategy	[44]	or	compare	it	to	depletion	protocols	[45]	acknowledge	the	expected	compression	of	the	dynamic	range	of	serum	protein	concentrations.
The	following	are	the	supplementary	data	related	to	this	article.
Supplementary	Fig.	1	2DE	map	analysis	of	control	serum	(upper	left	panel)	vs	three	ligand	library	bead	eluates.	The	first	elution	was	accomplished	by	using	three	column	volumes	of	TUC	solution	(2		M	thiourea,	7		M	urea,	2%	CHAPS)	followed	by	the
second	elution	using	three	volumes	of	an	aqueous	solution	of	9		M	urea,	pH		3.5	(pH	adjusted	with	citric	acid).	A	third	elution	was	then	performed	with	a	solution	composed	of	acetonitrile,	isopropanol,	trifluoroacetic	acid,	and	water	in	the	following
volumetric	proportions:	16.6,	33.3,	0.5,	and	49.5%.	(From	[41]).
alt-text:	Supplementary	Fig.	1
Supplementary	Fig.	2	2DE	of	eluates	from	0-mer	(beads	without	peptides)	to	6-mer	as	a	sequence	of	columns	compared	to	the	initial	RBC	lysate	and	to	the	eluate	from	a	hexapeptide	column	directly	loaded	with	the	RBC	lysate.	The	total	number	of	spots
counted	per	map	is	marked.	(From	[42]).
alt-text:	Supplementary	Fig.	2
Supplementary	Fig.	3	Number	of	proteins	identified	in	samples	treated	with	combinatorial	peptide	ligand	library	(CPLL)	beads	vs	the	untreated	extract,	as	a	function	of	copies/cell:	all	proteins	(left	panel)	and	unshared	proteins	(right	panel);	data	for
yeast	cell	proteins	(S.	cerevisiae	strain	S288C,	BY4741).	(Redrawn	from	[43].)
alt-text:	Supplementary	Fig.	3
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